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ABSTRACT 
 
 Herbimycin A (1) belongs to the ansamycin family and is a 19-membered lactam 
with seven stereogenic centres, making it a synthetic challenge, which was first isolated 
in 1979 by Omura et al. Herbimycin A (1) exhibits a broad spectrum of biological 
activities: herbicidal, inhibitor of angiogenesis and of the maturation of growth factor 
receptor tyrosine kinases. 
 
 
Figure 1 - Herbimycin A 
 
 Since its discovery, only three total syntheses of Herbimycin A (1) have been 
described in the literature, along with the syntheses of advanced fragments. 
 
 This thesis describes a new route to Herbimycin A (1), using a wide range of 
chemical reactions than those used in the previous routes from the literature. 
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 The main idea is to split Herbimycin A (1) into an aromatic fragment and an 
aliphatic fragment as shown below in Scheme 1. 
 
 
Scheme 1 - Retrosynthesis highlighting both aromatic and aliphatic fragments 
 
 The synthesis of aliphatic fragment (4) follows up the work of Ansell and 
Pietsch, past members of the Parsons group. 
 
 Interesting results could be obtained and a wide range of Organic Chemistry 
reactions could be investigated. 
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HERBIMYCIN A 
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I. The Ansamycin Antibiotics 
 
Herbimycin A (1) belongs to the family of the ansamycin macrolide antibiotics. 
Ansamycins are named so, because of their basket-like molecular architecture, being 
benzenoid or naphthalenoid aromatic compounds in which non-adjacent positions are 
linked by a polyketide derived aliphatic chain (Latin: ansa = handle) to form a cyclic 
structure
1
. 
 
 
Figure 2 - Herbimycin A (1) 
 
One of the aliphatic-aromatic junctions is always an amide bond. These 
macrolactams are an interesting synthetic challenge as they contain many chiral centres.  
 
Herbimycin A (1) was isolated in 1979 by Omura and co-workers from the 
fermentation broth of Streptomyces hygroscopicus strain AM-3672
2,3
 pictured in  
Figure 3. 
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Figure 3 - Streptomyces hygroscopicus AM-3672
3
 
 
It was discovered, based on detailed spectroscopic analyses
4,5
 that herbimycin A 
(1) was a 19-membered lactam ring with seven stereogenic centres, a carbamate, an 
isolated trisubsituted (E)-double bond, and (E,Z)-diene plus a benzoquinone ring system. 
 
The first ansamycin shown to contain a benzoquinone moiety was geldanamycin 
(5) and was isolated for the first time in 1970 from Streptomyces hygroscopicus var
6
. 
 
 
Figure 4 - Geldanamycin (5) 
 
It was worth noting that several ansamycins such as herbimycin B
7
 (6) and C
8
 
(7), the dihydroherbimycins A
9
 (8) and C
11
 (9), as well as macbecin
10
 I (10) and II (11), 
have a close structure to herbimycin A (1). 
  
Figure 5 - The herbimycins 
Herbimycin A (1) R=Me, R’=OMe 
Herbimycin B (6) R=H, R’= H 
Herbimycin C (7) R=Me, R’=H 
 
 
 
Figure 6 - The dihydroherbimycins 
Dihydroherbimycin A (8) R= Me 
Dihydroherbimycin C (9) R=H 
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Figure 7 - Macbecin I (10) and macbecin II (11) 
 
The natural ansamycins are split in different groups according to the nature of the 
aromatic moiety and the length of the aliphatic chain. Each group exhibits different 
biological activities. 
 
The main prominent ones containing a naphthalenoid part and a 17-C atom 
chain, show selective antibacterial activity and inhibit RNA polymerase. The rifamycins, 
such as rifamycin B (12) are of clinical importance
11
. 
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Figure 8 - Rifamycin B (12) 
 
The benzenoid ansamycins with a 15-C chain include the ansamitocins, for 
instance, ansamitocin P-3 (13), along with the maytansine
12
 (14) known for their anti-
tumour activity
13
. 
 
 
Figure 9 - Ansamitocin (13) and maytansine (14) 
 20 
 
 
II. Biological Activity 
 
1. Herbicidal activity 
 
The herbicidal activity of herbimycin A (1) was tested by planting seeds of 
various monocotyledonous and dicotyledonous plants
2,7
. Two systems were used in 
treatments with herbimycin A (1). The pre-emergence system was conducted before 
germination of the seeds and the post-emergence, 1 to 2 weeks after germination by 
foliar spraying. Herbicidal effects were examined after treatment with herbimycin A (1) 
and evaluated. As shown in Table 1, herbimycin A (1) was found to exhibit potent 
herbicidal activity against most mono- and di-cotyledonous plants. 
 
 
 21 
 
 
 Test Plant 
Pre-emergence 
system
*
 (g/area) 
Post-emergence 
system
*
 (g/area) 
100 50 25 12.5 100 50 25 
Monocotyledon 
Oryza sativa 2 1 1 0 0 0 0 
Echinochola crus-galli 5 5 5 4    
Digitaria adescendens 5 5 5 4 5 4 4 
Cyperus microiria 5 5 5 5 5 5 5 
Dicotyledon 
Chenopodium ficifolium 5 5 5 4 5 5 5 
Portulaca oleracea 5 5 5 4 4 4 3 
Galinsoga ciliata 5 5 5 4 4 3 2 
Rorippa atrovirens 5 5 4 4 5 4 3 
 
 
*
0 = no activity; 1 = less than 20%; 2 = 20 to 40%; 3 = 40 – 70%; 4 = 70 - 90% and 5 = 90-100%. 
Table 1 - Herbicidal activity of herbimycin A (1) 
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2. Anti-tobacco mosaic virus activity 
 
Iwai and co-workers observed that both herbimycin A (1) and B (6), macbecin I 
(10) and geldanamycin (5) had activities against anti-tobacco mosaic virus (TMV). 
TMV, one of the simplest viruses known, is an RNA virus that causes mosaic disease in 
tobacco and similar effects in other plants.  
 
 
Figure 10 - Tobacco mosaic virus - Systemic infections of Nicotiana tabacum cv. Turk 
plants showing TMV-associated mosaic
14
 (Photo: Karen-Beth G. Scholthof). 
 
The obtained results of the study are compared in Table 2.  
 23 
 
Antibiotic Concentration (ppm) Inhibition (%) 
Herbimycin A (1) 
25.0 95 
12.5 90 
6.2 92 
3.1 85 
Herbimycin B (6) 
25.0 100 
12.5 93 
6.2 88 
3.1 58 
Geldanamycin (5) 
25.0 99 
12.5 98 
6.2 98 
3.1 30 
Macbecin I (10) 25.0 53 
 
Table 2. Anti-TMV activity of herbimycins, geldanamycin and macbecin I 
 
This finding was new in a sense that no ansamycin antibiotic had previously been 
reported to have herbicidal activity.  
 
3. Inhibition of macromolecular synthesis in ts/NRK cells 
 
Herbimycin A (1) was later on re-isolated as an active substance which reversed 
the transformed morphology of temperature-sensitive Rous sarcoma virus-infected rat 
cells (ts/NRK) to the normal morphology at a permissive temperature (33°C)
15
. 
Rous sarcoma virus is an oncogenic virus, that is, a virus capable of causing a 
sarcoma cancer. 
 24 
Uehara and his team
16
 showed that Herbimycin A (1) inhibited DNA synthesis 
with little or no inhibition of RNA and protein syntheses at the concentrations 
corresponding to their IC50.  
 Inhibition (%) 
DNA 85.5 
RNA 7.0 
Protein 11.0 
 
Table 3. Effect of herbimycin A (1) on macromolecular syntheses in ts/NRK cells 
 
4. Chemical modification and antitumor activity 
 
Several halogenated and other analogues have been synthesized, and evaluated in 
vivo regarding their activities against Ehrlich ascites carcinoma
17,18
. Ehrlich ascites 
carcinoma (EAC) is one of the commonest experimental tumors. EAC is referred to as 
an undifferentiated carcinoma which has high transplantable capability, no-regression, 
rapid proliferation, shorter life span, 100% malignancy and also does not have tumor-
specific transplantation antigen (TSTA)
19
. 
 
EAC is similar to human tumours which are the most sensitive to chemotherapy 
as they are undifferentiated and as they present a rapid growth rate. 
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Scheme 2 
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Some derivatives showed to be even more active than Herbimycin A (1). 
 
Compound 
Total dose 
(mg/kg) 
Dose (mg/kg x day) T / C (%) 
Number of 
living*/total 
Herbimycin A (1) 6.3 1.3 x 5 126 1/4 
1 (15) 125 25.0 x 5 193 3/4 
2 (16) 250 50.0 x 5 215 4/4 
3 (17) 125 12.5 x 5 200 4/4 
4 (18) 250 50.0 x 5 190 4/4 
5 (19) 125 25.0 x 5 134 1/4 
6 (20) 125 25.0 x 5 89 0/4 
7 (21) 250 50.0 x 5 200 3/4 
8 (22) 250 50.0 x 5 150 2/4 
*Number of surviving mice at day 31. 
Table 4. Antitumor activity of Herbimycin A analogues  
against Ehrlich ascites carcinoma 
 
As you can notice from Table 4, the derivatives modified at the 4, 5, 6, and  
7-positions of the ansa-chain showed particularly high activities.  
 
 
5. Mechanism of anti-proliferative and anti-tumor activity 
 
Herbimycin A specifically inhibits the cytosolic chaperone HSP 90 (Heat Shock 
Protein) and its endoplasmic reticulum (ER) homologue GRP 94.  
 
 27 
Heat shock proteins are called molecular chaperones. Their production is 
triggered when a cell is subjected to stress situations, such as undesired chemical 
influences or high temperatures
20
. They prevent the non-specific aggregation of proteins 
and assist in their folding and refolding
21
. 
One of the main roles of the HSP 90 chaperone is the activation of different 
families of protein kinases, which play a major role in cancer
22
.  
 
Herbimycin A has anti-proliferative and anti-tumor effects: as it binds to HSP 90, 
inhibiting the HSP 90 - mediated conformational maturation/re-folding reaction, thereby 
promoting degradation of HSP 90 substrates
23,24
. 
 
SRC (sarcoma) kinases are important during the cell cycle. As a consequence, 
much attention is being focused in order to act on them for therapeutic purposes. A 
screening of natural products has been performed whose aim was the inhibition of the 
transforming activity of tyrosine kinase oncogenes. Herbimycin A (1) was found to 
exhibit inhibitory activity
25
. 
 
Later on, a study showed that drug-induced reversion could be achieved without 
any direct inhibition of the SRC phosphorylating agent but that the ansamycins directly 
bind to HSP 90
26
. 
 
It is known that herbimycin A (1) and geldanamycin (5) bind to the adenosine 
triphosphate (ATP) binding pocket of HSP 90, which is located in the N-terminal of the 
protein
27,28
. 
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Stebbins and his team were able to obtain a crystal structure of the HSP 90 - 
geldanamycin complex and observed geldanamycin (5) bound to the ATP binding site in 
a C-clamp like structure, where the benzoquinone forms the top of the C and the ansa 
ring the stem and bottom (see Figure 11)
22
. This observation led to interesting 
conclusions regarding the structure-activity relationship of geldanamycin (5) and its 
inhibitory effects. 
 
 
 
Figure 11 - X-Ray structure of HSP 90 - geldanamycin (5) complex by Stebbins
22
 
 
 
 However, due to high levels of toxicity, geldanamycin (5) cannot be used as a 
therapeutic agent. Analogues have been sought after and the main focus for structural 
modification is the C-17 methoxy group. Schnur et. al. showed that the highest potency 
was obtained when an amino group was present at the C-17 position
29,30
.  
 29 
 
The synthesis of 17-aminoallylgeldanamycin often referred to as 17-AAG or 
now tanespimycin (23) shown below was a major breakthrough, as it proved to be more 
stable and less toxic than geldanamycin (5)
31
. In addition, it shows a higher affinity for 
HSP 90 derived from tumour cells compared to normal cells
32
. Tanespimycin (23) has 
been in clinical trials since 1999. It is currently in phase II trials against melanoma
33,34
, 
breast
35
, prostate
36
, and thyroid
37
 cancer.   
 
 
Figure 12 - Tanespimycin (23) 
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III. Biosynthesis 
 
As mentioned earlier, Herbimycin A (1) is produced by Streptomyces 
hygroscopicus strains. The biosynthesis of Herbimycin A (1) involves at first the 
formation of 3-amino-5-hydroxybenzoic acid (AHBA) (34), by a variant of the 
Shikimate pathway
38
. 
 
Scheme 3 – Biosynthesis of AHBA following the Shikimate pathway38 
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AHBA (34) then serves as the starter unit for the assembly of a polyketide to 
form the carbon skeleton of (1). This formation is catalyzed by a special enzyme called 
polyketide synthase (PKS), made of sets of active sites called modules. 
 
Each module contains the catalytic domains required for a single round of 
polyketide chain elongation by substrate condensations and various reductions or 
dehydrations. During each extension step of one unit, the polyketide chain is elongated 
with two carbon atoms, where the β-carbon is a keto group. Then, post-PKS tailoring 
steps further modify the PKS product to give (1). 
 
In 2005, Rascher et al.
39
, from Kosan Biosciences, Inc., in California published 
their results about the biosynthesis of herbimycin A (1) obtained by gene sequencing and 
disruption. They proposed that C-21 oxidation, C-17 oxidation and  
O-methylation, along with C-7 carboymylation and C-4 and C-5 dehydrogenation occur 
after polyketide chain assembly, as outlined in Scheme 4 below. 
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CHAPTER 2 
 
PREVIOUS SYNTHESES 
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Since its discovery, only three total syntheses of herbimycin A (1) have been 
described in the literature, although there have been many syntheses of advanced 
fragments. In addition, related ansamycin benzoquinone compounds such as the 
macbecins (10) and (11) and geldanamycin (5) have been extensively studied in the past.  
 
I. Tatsuta’s total synthesis: 
 
Tatsuta and co-workers
40,41
 reported the first total synthesis of herbimycin A (1) 
in 1991, which also confirmed the compound’s absolute stereochemistry. The 
retrosynthetic pathway Tatsuta and his team proposed is pictured in Scheme 5.  
 35 
 
Scheme 5 – Retrosynthetic path 
 
Formation of the quinone and construction of the carbamate unit were carried out 
after the macrocyclisation step to furnish herbimycin A (1). Intermediate (35) was the 
result of several group manipulations, including a Still-Gennari olefination
42
 and a 
Wittig reaction. The route the author proposed was to install both C6 and C7 chiral 
centres prior to performing the coupling of the aromatic unit. 
 36 
As a consequence, intermediate (36) was divided into two portions being the 
aromatic chromophore (37) and the aliphatic aldehyde (38). The aldehyde would be 
obtained by elongation of the the C9-C15 portion (39) which would again be derived 
from the chiral sugar, methyl -D-mannopyranoside (40) (Scheme 5). 
 
The synthesis of the aldehyde (38) began with conversion of methyl α-D-
mannopyranoside (40) into the epoxide (41). This was regioselectively opened using 
bis(1,2-dimethylpropyl)borane to give a 6:1 ratio in favour of the desired regio-isomer 
(42), corresponding to the necessary stereochemical relationships at the C12 and C14 
positions in herbimycin. The resulting alcohol (42) was subsequently converted to 
alkene (43) in several steps (Scheme 6). 
 
 
Reagents and conditions: a) Bis(1,2-dimethylpropyl)borane (8 eq), NaBH4 (0.25 eq), THF, 25 °C, 83 %. 
Scheme 6 – Epoxide opening 
 
The authors introduced the syn relationship between the C11 alcohol and the C10 
methyl substituents by treating olefin (43) with dicyclohexylborane in tetrahydrofuran 
followed by subsequent work-up with basic hydrogen peroxide to produce the undesired 
anti product (44) and the desired syn product (45) in 66% and 15 % yields respectively. 
 37 
However, when borane dimethyl sulfide complex was used in tetrahydrofuran, alcohol 
(45) was formed upon hydroperoxide work-up, in an 83 % yield, with only 17 % of its 
undesired C10 isomer (44) (Scheme 7). 
 
 
Reagents and conditions: BH3·SMe2, THF, 25 °C, then H2O2(aq), NaOH, 83 % of (45),  
(dr = 1:5, (45:44)). 
Scheme 7 - Syn selective hydroboration 
 
The mixture of both 1,3-diol (44) and (45) was converted to the acetal using 
benzaldehyde dimethyl acetal in dichloromethane and a substoichiometric amount of  
10-camphorsulfonic acid. Terminal alcohol (46) was oxidised following Swern’s 
procedure to give aldehyde (47) in an 89 % (Scheme 8). 
 
 
Reagents and conditions: a) PhCH(OMe)2, CSA, CH2Cl2, 25 °C, 90 %; 
 b) (COCl)2, Me2SO, Et3N, CH2Cl2, 89 %. 
Scheme 8 
 
Aldehyde (48), obtained from intermediate (47) after several steps, underwent 
Correy-Schlessinger’s olefination43 with N-[2-(triethylsilyl)propylidene]-t-butylamine 
 38 
and s-butyllithium in tetrahydrofuran followed by an aqueous oxalic acid work-up 
yielding the (E)-unsaturated aldehyde (49) in an 85% yield as a single isomer, 
corresponding to the C7-C15 fragment. This fragment was then allylated using [(Z)-3-
methoxyallyl]-diisopinocampheylborane, prepared according to Brown’s procedure44 
resulting in the desired C7-C6 syn product (50a) in a 76 % yield, along with a 14% yield 
of the undesired diastereoisomer (50b).  
 
 
Reagents and conditions: a) N-[2-(triethylsilyl)-propylidene]-t-butylamine, s-BuLi, THF, -78 ºC to  
-20 ºC, oxalic acid work-up, 85 %; b) [(Z)-3-methoxyallyl]-diisopinocamphenylborane, THF,  
-78 ºC to -20 ºC, 90 %, (dr = 6:1, (49:50)). 
Scheme 9 
 
Once the aliphatic fragment (38) was obtained it was then coupled to the 
aromatic sub-unit (51), which was prepared from 3-bromo-2,5-dimethoxyaniline in a 
98% yield.
45
 It led to a separable mixture of the 15R (54) and the 15S (53) isomers in a 
1:1 ratio and 91 % yield. The structure of the desired diastereomer (54) was confirmed 
by comparing the proton NMR spectrum with similar intermediates that Baker et al.  had 
 39 
synthesised in their work on macbecin 1 (10).
46
 The authors could convert the undesired 
isomer (53) to the desired one (54) by an oxidation-reduction procedure
47
 using lithium 
aluminium hydride and (+)-(2S,3R)-4-dimethylamino-3-methyl-1,2-diphenyl-2-butanol 
(chirald®) in a solution of 1% of tetrahydrofuran in diethyl ether at  
-78 ºC (Scheme 10). The concentration of tetrahydrofuran in the reaction was essential to 
reach a 4:1 ratio of 15R (54) and 15S (53) diastereoisomers
48
. 
 
 
 
Reagents and conditions: a) n-BuLi, THF, -78 ºC, 91 %, (dr = 1:1, (53:54)); b) Me2SO, Ac2O,  
95 ºC, 80 %; c) LiAlH4, (chirald®), 1 % THF/Et2O, -78 ºC, 80 %, (dr = 4:1, (54:53)). 
Scheme 10 
 
The synthesis proceeded with methylation followed by cleavage of the terminal 
alkene using either osmium tetroxide/sodium periodate or by treatment with osmium 
tetroxide, 4-methylmorpholine-N-oxide followed by lead tetra-acetate, to give aldehyde 
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(55). The following steps were similar to those employed by Baker and his team for the 
total synthesis of macbecin I (10)
46
. A Still-Gennari olefination42 using potassium 
bis(trimethylsilyl)amide, 18-crown-6 in tetrahydrofuran at -78 ºC was followed by a 
reduction and then an oxidation leading to aldehyde (56) (Scheme 11). 
 
 
Reagents and conditions:  a) MeI, NaH, DMF, 0 °C; b) OsO4-NaIO4,THF-pH 7, phosphate Buffer, rt.; 
c) OsO4-NMO, H2O/(Me)2CO, rt, then Pb(OAc)4, AcOK, MeCN, 0 °C; d) (CF3CH2O)2P(O)CH2COOMe, 
KN(SiMe3)2, 18 – crown - 6, THF, -78˚C, 4 h, (63 % and 73 % respectively over three steps); e) DIBAL, 
toluene, -78˚C, 1 h;  f) PDC, CH2Cl2, 25˚C , 24 h. 
Scheme 11 
 
A subsequent Wittig reaction using the stabilised ylide 1-carboethoxy 
ethylidenetriphenylphosphorane led to the E/Z-diene (57) in a 70% yield over three 
steps. Saponification and macrolactamisation with bis(2-oxo-3-oxazolidinyl)phosphinic 
chloride and N-ethyldiisopropylamine
49 
in toluene at 85ºC led to the desired macrocycle 
(58) in an overall yield of 72 % from aldehyde (56) (Scheme 12). 
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Reagents and conditions:  a) Ph3P=C(Me)COOEt, CH2Cl2, 40˚C, 22 h; b) 0.02% HCl-MeOH, 25˚C, 
 0.5 h;  c) LiOH, 2 : 2 : 1 THF – MeOH - H2O, 25˚C, 29 h;  d) BOP-Cl, DIPEA, toluene, 85˚C, 15 h, , 72 
% over 4 steps. 
Scheme 12 
Only three steps were left to reach herbimycin A (1): a desilylation using 
tetrabutylammonium fluoride, followed by carbamoylation with sodium cyanate and 
trifluoroacetic acid in dichloromethane
50
 and finally an oxidative de-O-methylation 
using silver (II) oxide and 1 M aqueous nitric acid in dioxane. This gave herbimycin A 
(1) in a 91% yield from (58) (scheme 13)
51
 and also allowed Tastuta to confirm the 
structures absolute stereochemistry for the first time.  
 
 
Reagents and conditions:  a) TBAF, THF, 25 ºC, quant.; b) NaOCN, TFA, CH2Cl2, 25 ºC, 91 %; c) 
AgO, 1M HNO3(aq), dioxane, 25 ºC, 100 % (91 % over three steps). 
Scheme 13 
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II. Kallmerten’s partial synthesis 
 
 In 1993, Kallmerten
52
 reported the synthesis of the C5-C12 subunit (59) of 
herbimycin A (1) where the key transformation was a diastereoselective [2,3] Wittig 
rearrangement of the glucose derived tertiary allylic ether (60).  
 
 
Scheme 14 
 
 Kallmerten started the synthesis with the commercially available 
glucofuranose (61) that was turned into iodo-alcohol (62) over eleven steps. The iodide 
(62) was then treated with Zinc dust in ethanol resulting in the cyclised lactol (63) as a 
mixture of anomers. The lactol (63) underwent a reduction, followed by a mono-
benzylation of the resulting diol to yield tertiary allylic alcohol (64). Oxazoline (60) was 
then formed and was treated with lithium diisopropylamide and a [2,3] Wittig 
rearrangement took place to produce oxazoline (59) as a single product. (59) was then 
turned, after two steps, into (65) which corresponds to the right C5-C12 precursor of 
herbimycin A (1), bearing 4 of its 7 chiral centres. 
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Reagents and conditions: a) Zn, EtOH; b) LiBH4, THF; c) PhCH2Br, NaH, DME, 79 % over three steps; 
d) KH, 2-chloromethyl-4,5-dihydro-4,4-dimethyloxazole, DME; e) LDA, THF, -78 to 0˚C, 78 % over two 
steps. 
Scheme 15 
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III. Martin’s partial synthesis 
Martin reported the synthesis of an advanced intermediate (67) toward the total synthesis 
of herbimycin A (1), containing C3-C15 with the correct stereochemistry
53
. The key 
steps of this synthesis were the transformations of furans (69) and (71) to pyran (68) and 
dihydropyran (70) respectively (Scheme 16). These reactions had been previously 
described by Martin when he worked on the total synthesis of  
(+)-macbecin 1 (10)
54
. The coupling of both pyrans (68) and (70) led to the trisubstituted 
E-double bond between C8 and C9 in herbimycin. 
 
 
Scheme 16 
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 The authors started with the known aldehyde (72) which reacted with furyl 
lithium to yield a separable mixture of epimeric diols (73). The desired diol (71) was 
oxidized to give the intermediate hydropyranone then cyclized under dehydrating 
conditions to furnish the enone (74). Selective reduction of the ketone in (74) was 
performed via the use of Yamamoto’s bulky DIBAL-BHT reagent55, followed by 
methylation to give the ether (75). The ketal was hydrolysed by treatment with acid and 
subsequently oxidised using the Swern procedure
56
 to produce ketone (76). The obtained 
ketone (76) was then turned into vinyl iodide (77) following the Barton vinyl iodine 
procedure
57
 (Scheme 17). 
 
Reagents and conditions: a) furan, n-BuLi, THF, -70 to 0˚C; b) TBAF, THF, rt; c) O2, CH2Cl2/MeOH, 
Me2S; d) p-TsOH, benzene, MeCN, MgSO4; e) DIBAL-BHT; f) KH, MeI; g) PPTS, MeOH;  
h) DMSO,(COCl)2, Et3N, CH2Cl2, -60˚C; i) NH2NH2, I2, Et3N. 
Scheme 17 
 
 Then, Martin and his team proceeded to a metal-halogen exchange with (77) 
which reacted with (68) to give alcohol (78) as a mixture. (78) was then converted to 
xanthates which underwent thermal isomerization via a [3,3]-sigmatropic rearrangement 
leading to the mixture of allylic dithiocarbonate (79). 
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(79) was then reduced to yield alkene (69) along with the disusbstituted alkene 
(80). Desired (69) had its silyl protecting group removed to give lactol (81). 
 
 
Reagents and conditions: a) t-BuLi, Et2O, -95˚C; b) NaH, CS2, THF, MeI; c) benzene, Δ; d) Bu3SnH, 
AIBN, toluene, Δ; e) TBAF, HOAc, THF, rt. 
Scheme 18 
  
 The authors could achieve the coupling of the aromatic fragment (83) with lactol 
(81) to obtain a mixture of (84). The desired isomer proved to be a suitable precursor to 
herbimycin A (1) (Scheme 19). 
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Reagents and conditions: a) t-BuLi, TMEDA, Et2O, -20˚C, then dilute HCl, 38 %. 
Scheme 19 
IV. Panek’s total synthesis 
 
Panek and co-workers
58
 published the second total synthesis of herbimycin A (1) 
in 2004. The key step of their approach was an asymmetric crotylsilation that had been 
previously developed for their total synthesis of macbecin (10)
59
 which constructed four 
of the seven necessary stereocentres of the target molecule. 
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Scheme 20 –Panek’s retrosynthetic route 
 
 Macro-lactamisation would be the final step and a Horner-Emmons olefination 
installed the sensitive E/Z-diene system. The C6-C7 bond was the result of Brown’s 
allylation
44
 and the stereo-centre at the C12 position was formed by the hydroboration 
reaction investigated by Panek
59
. 
 
 
 The synthesis started with alcohol (88) which had been previously synthesised 
during Panek’s total synthesis of macbecin 1 (10) (Figure 13)59:  
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Figure 13 
 
 
The aromatic acetal (89) was built from p-methoxyphenol
60,61
 and underwent a 
syn-crotylation with (E)-crotyl silane (90) using trimethylsilyl triflate in 
dichloromethane at -78 °C, to give the corresponding ester (91) in an 89 % yield 
(Scheme 21). 
 
 
Reagents and conditions: TMSOTf, CH2Cl2, -78 ºC, 89 %, (dr = >30:1); 
Scheme 21 
 
In the past, Panek had investigated syn crotylation reactions with (E)-crotyl 
silanes of the general structure (92) (Figure 14) acting as carbon nucleophiles in the 
addition to aldehydes and pre-formed acetals, leading to homo-allylic ethers with high 
stereo-selectivity
59
. 
 50 
 
Figure 14 
  
When reacting -methyl-β-(dimethylphenylsilyl)-(E)-hexenoates (92a) and 
(92b) with aryl acetals (89), in the presence of a Lewis acid, Panek observed the 
preferential formation of the E-alkene with high syn-stereoselectivity. Indeed, chiral 
centres at the C5 and C6 positions of the products (94a) and (94b) were obtained with an 
e.e .of greater than 95 % (Scheme 22)
 62,63
. 
 
 
Reagents and conditions: TMSOTf, CH2Cl2, -78 ºC 
Scheme 22 
 
  
The crotyl silane reagents (92) behaved as carbon nucleophiles, attacking the in 
situ generated oxonium ion
64
 (93), formed from the corresponding acetal, when treated 
with a Lewis acid. 
 
Panek based his mechanism on an anti-SE addition model depicted in  
Scheme 23
65
. 
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Scheme 23 - E-selectivity 
 
In order not to have any steric strain (A
1,3
-strain) (99), the smallest substituent, in 
this case hydrogen, is placed in an eclipsing position to the adjacent double bond
66
 
yielding the favoured conformer (96). The silicon moiety being bulky, it then directs the 
approach of the electrophile onto the opposite face of the π-system, thus giving the 
carbocations (97) and (100). The C-Si bond switches then to a periplanar position with 
regards to the p-orbital through bond rotation, allowing stabilisation of the carbocation 
through hyperconjugation, thus giving the favoured E-alkene (98) or the unfavoured  
Z-alkene (101). 
 
 With regards to the resultant stereo-chemistry, Panek based his explanation on an 
antiperiplanar transition state model which described the interaction between the 
crotylsilane and the oxonium ion. Panek suggested that the participating π-bonds were 
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orientated at a 180º angle to each other. The nucleophilic carbon and the activated 
carbonyl adopted a co-planar anti-relationship (Scheme 24). 
 
 
Scheme 24 – Syn-selectivity 
 
The ester (103) was then treated with borane dimethyl sulfide complex in 
tetrahydrofuran, and subsequently oxidized with alkaline hydrogen peroxide, leading to 
the required diol (104) in an 85 % yield with a dr of up to 11:1 (Scheme 25). 
 
 
Reagents and conditions: BH3·SMe2, NaOOH, THF, 85 %, (dr = 11:1, (104:105)). 
Scheme 25 
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Panek proposed the following intramolecular mechanism to explain the resulting 
stereochemistry of this hydroboration step (Scheme 26)
67
. 
 
 
Scheme 26 – Intra-molecular hydroboration according to Panek67 
 
 As shown above the ester group was first reduced, resulting in a directing alkoxy 
group, thus leading to good levels of regio- and diastereoselectivity  
(Scheme 26)
68
. The author suggested the OBn group, adjacent to the carbonyl led to a 
polarization of the double bond; thus reinforcing the positional and facial selectivity in 
favour of the desired product. 
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A further five steps were necessary to furnish the aldehyde (109) in an overall 
yield of 56% before performing the silyl-crotylation reaction (Scheme 27). 
 
 
Reagents and conditions: a) TMSOTf, TMSOMe, 59 %, (dr = 12:1). 
Scheme 27 
 
Ester (111) was subsequently turned into aldehyde (112) in a 61 % yield via 
oxidative cleavage and reduction. A Wittig olefination, followed by reduction and a 
Swern oxidation led to the tri-substituted E-alkene (113) in an overall yield of 57 % 
yield (Scheme 28).  
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Reagents and conditions: a) Ph3P=C(Me)CO2Et, toluene, 78 %; b) DIBAL-H, THF, 80 %;  
c) (COCl)2, Me2SO, 91 %. 
Scheme 28 
 
Brown allylation
44
 allowed the authors to install the chiral centres at the C6 and 
C7 positions (Scheme 29). 
 
 
Reagents and conditions: THF, -78 ºC, 77 %. 
Scheme 29 
 
Panek used the -methoxyallyl organoborane reagent (114) derived from  
(-)--pinene to give a 77% yield of the alcohol (108) as a single diastereoisomer 
(Scheme 29)
58
. 
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After performing a silyl protection and an oxidative cleavage of the terminal 
alkene (115), aldehdye (116) underwent an olefination
69
 using the Still-Gennari 
phosphonate
42
. The Z-,β-unsaturated ester (117) was subsequently turned in two steps 
into its corresponding aldehyde (118) in an overall yield of 89% before being subjected 
to Wittig’s conditions using the stabilised ylide 1-carboethoxyethylidenetriphenyl-
phosphorane. The E/Z-diene system (118) was obtained in a 99 % yield (with a  
dr = >30:1, (E:Z)). The nitro group was reduced based on Lalancette’s procedure70 using 
NaBH2S3, which was followed by a saponification of the ethyl ester, leading to the 
carboxylic acid (119) (Scheme 30). 
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Reagents and conditions: a) (CF3CH2O)2P=O(CH2)CO2Me, KHMDS, 18-crown-6, 83 %; 
b) Ph3P=C(Me)CO2Et, toluene, 99 %, (dr = >30:1, (E:Z)); c) NaBH2S3, THF, 83 %; 
d) LiOH, MeOH/THF/H2O (2:2:1), quant. 
Scheme 30 
 
Panek then carried out the final four steps according to Tatsuta’s procedure40,41 
shown on Scheme 12 and  Scheme 13: macrolactamisation, desilylation and carbamate 
formation led to alcohol (120) (Scheme 31)
71
. Formation of the quinone was performed 
with ceric ammonium nitrate, leading to herbimycin A (1) in 27 steps from (89) and (90) 
in an overall yield of 1.1%. 
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Reagents and conditions: a) BOP-Cl, DIPEA, 81 %; b) TBAF, 73 %;  
c) Cl3CCONCO, MeOH, K2CO3, 97 %; d) CAN, MeCN/H2O (2:1), 63 %. 
Scheme 31 
V. Cossy’s total synthesis 
 
The most recent total synthesis of herbimycin A was that reported by the group 
of Cossy
72
 in 2007. Their synthesis was novel in the sense that five of the structures 
seven chiral stereocentres of were installed based on allyl-metal methodologies, where 
the Z-alkene of the E/Z-diene system was installed through a Ring Closing Metathesis 
(RCM)
 73
. 
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Scheme 32 – Cossy’s retrosynthetic analysis72 
 
 The above retrosynthesis shows that the final step of the synthesis would be a 
macrolactamisation starting from acid (85). The E-double bond of the E/Z-diene system 
would be set up thanks to a Wittig olefination carried out on lactol (121), which would 
be formed via a ring closing metathesis of diene (122). Further simplification of (122) 
led to a disconnection between herbimycin A’s (1) aromatic portion and the C-15 
methoxy aliphatic chain generating fragments (123) and (124). The stereo-centre at C12 
would be controlled by an allyltitanation and the C10, C11 and C6, C7 stereogenic 
centres would be the result of a syn-crotylboration and a syn-alkoxyallylboration, 
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respectively. The commercially available Roche
®
 ester (125), bearing the correct 
setereochemistry at C13, acted as the starting point for this synthesis. 
 
 To start with the synthesis of fragment (124), aldehyde (126) was obtained in 
four steps from Roche ester (125). Aldehyde (126) underwent a stereoselective 
allyltitanation
74,75
 by treatment with Hafner’s allyl titanium reagent (S,S)-(128), shown 
in Figure 15 (Scheme 33). 
 
 
Reagents and conditions: a) (S,S)-(128), Et2O, -78 ºC, 96 %, (dr = >95:5). 
 
Scheme 33 
 
 
Figure 15 - Hafner’s titanium reagents74 
 
A range of titanium reagents derived from cyclopentadienyl titanium trichloride 
(CpTiCl3) were investigated by Hafner and his group. The best results were obtained 
with titanium reagents (128) and (129) which enable the transfer of allyl groups with 
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very high diastereofacial selectivity
76
.  Either alcohol (131) or (132) were obtained, 
depending if (R,R)-(129) or (S,S)-(128) was used (see Figure 15), with a diastereomeric 
ratio of 98:2 (Scheme 34). According to Hafner, the selectivity is more likely to be due 
to electronic rather than steric effects. 
 
 
Reagents and conditions: a) (R,R)-(129), THF, -78 ºC, 80 % of (131); b) (S,S)-(128), THF, -78 ºC, 71 % 
of (132), (dr = 98:2). 
Scheme 34 
 
Thanks to Hafner’s74 titanium reagent (S,S)-(128) (Figure 15), Cossy obtained 
alcohol (127) in a 96 % yield and with a 95:5 diastereomeric ratio (Scheme 34). 
 
Alcohol (127) was then methylated before performing the isomerisation
77
 of the 
terminal double bond of alkene (133) in a 98% yield using Grubbs’ 2nd generation 
catalyst (2 mol%) (Scheme 35)
78
. Treatment of alkene (134) with osmium tetroxide and 
sodium periodate followed, generating aldehyde (135), which was then used without any 
further purification. 
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Reagents and conditions: a) Grubbs II (2 mol %), N-allyl-N-tritylamine, DIPEA, toluene, 98 %;  
b) OsO4, NMO, Me2O/H2O (9:1), then NaIO4 (crude). 
Scheme 35 
 
The next step was to work on the stereocentres at C10 and C11. To do so, Cossy 
used tartrate crotylboronates, based on the methodology developed by Roush
79,80
, where 
the crotylation reactions he investigated controlled the syn/anti relationships; (E)-
crotylboronates tended to give anti C3-C4 alcohols (137) and (138) whereas 
 (Z)-crotylboronates syn C3 - C4 alcohols (139) and (140) (Scheme 36). However, the 
diastereofacial selectivity of the aldehyde was harder to achieve. 
 
 
Scheme 36 - Crotylboronation reactions investigated by Roush et al.
79
 
 
 
During the study of the application of enantiopure tartrate ester modified 
crotylboronates (141) and (142) (Figure 16) and their corresponding enantiomers, Roush 
and co-workers observed that when they were used with -methyl chiral aldehydes 
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(136), they were able to control the C4-C5 configuration as well as the C3-C4 one, thus 
allowing selective formation of (137) or (138) and (139) or (140) (Scheme 36)
79,80,81
. 
 
 
Figure 16 – (Z)- and (E)- crotylboronates80 
 
 
Roush proposed an empirical model to describe the reactivity of (141) and (142) 
shown in Scheme 37 and Scheme 38
82
. Diastereoisomers (137) and (139), formed via 
transition states (143) and (141), each with a 3,5 anti-relationship are intrinsically 
favoured
82
 whereas the 3,5-syn diastereoisomers (138) and (140) are intrinsically 
disfavoured due to the non-bonded interaction between the R group of the aldehyde and 
the methyl group of the crotyl reagent in transition states (144) and (142). 
 
 
 
Scheme 37 - Z-crotylboronates 
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Scheme 38 - E-crotylboronates 
 
 This methodology was used in the synthesis of herbimycin A (1) by Cossy and 
her team (Scheme 39)
72
. They assumed the -methoxy group in (135) would lead to the 
formation of the desired diastereoisomer (145) since R is larger than a methyl group. 
According to Roush’s model, the reaction is intrinsically favoured79. Crotylation of 
aldehyde (135) using the Z-crotylboronate (S,S)-(267) gave the desired diastereoisomer 
(145) in a 70 % yield (Scheme 39). The formation of any other diastereoisomer was not 
reported. 
 
 
Reagents and conditions: (S,S)-(267), 4 Å MS, toluene, rt to -78 ºC, then 2N NaOH (aq), 0 ºC,70 %. 
Scheme 39 – Crotylboronation installing both C10 and C11 stereo-centres 
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Successive methylation, dihydroxylation and cleavage starting from alcohol 
(145) gave aldehyde (146), which then underwent a Corey-Schlessinger olefination
43
 to 
get the α-β-unsaturated aldehyde (147) in a 93 % yield and an (E/Z)-ratio of 4:1. 
 
The desired C-6/C-7 syn product (148) was obtained via Brown’s allylation in a 
73% yield and a 4:1 diastereomeric ratio. Silyl protection, and selective deprotection 
followed by a Dess-Martin oxidation gave aldehyde (124) (Scheme 40). 
 
 
Reagents and conditions: a) N-[2-(triethylsilyl)-propylidene]-t-butylamine, s-BuLi, then citric acid, 
86 %, (4:1, (E:Z)); b) (114), s-BuLi, THF, -78 ºC, BF3·OEt2, -50 ºC to 0 ºC, 73 %, (dr = 4:1). 
Scheme 40 
 
 The authors prepared the aromatic subunit (123) in 4 steps starting from 
commercially available 4-methoxy-2-nitrophenol (149) with an overall yield of 49% 
(Scheme 41). 
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Scheme 41 
 Coupling both aliphatic (124) and aromatic (123) fragments could then take 
place by means of a lithium halogen exchange. Cossy’s team obtained a mixture of two 
diastereosiomers in an overall yield of 87% with a 1.6:1 ratio in favour of the desired 
Felkin-Ahn adduct (150) which could be isolated by silica gel chromatography, with a 
yield of 54 % (Scheme 42). 
 
 
Reagents and conditions: n-BuLi, Et2O, -78 °C to rt, then -78 °C, (150), 87 %, (dr = 1.6:1, (150:151)). 
Scheme 42 – Coupling reaction 
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The synthesis went on with the desired enantiomer (150) which underwent 
several steps leading to diene (151). Grubb’s 2nd generation catalyst was then used to 
perform a RCM with diene (151) to give lactone (152), which was converted to the 
corresponding lactol. The sensitive E/Z-diene system was subsequently installed using 
the stabilized ylide 1-carboethoxyethylidenetriphenylphosphorane (Scheme 43)
83
. 
 
 
Reagents and conditions: a) Grubbs II (20 mol %), toluene, Δ, 72 %; b) DIBAL-H, Et2O, -78 °C. 
then Ph3P=C(Me)CO2Et, toluene, Δ, (9:1, (E:Z)), (87 % over two steps). 
Scheme 43 
 
The end of the synthesis was based on the one Tatsuta
40 
and Panek
58
 reported 
(Scheme 44). The amine function of intermediate (153) was deprotected and a 
saponification was achieved before realizing the bis(2-oxo-3-oxazolidinyl)phosphinic 
chloride mediated macrocylization to give amide (120). 
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 Finally, a carbamate was formed at the desired C7 and the aromatic ring was 
oxidized by reaction with ceric ammonium nitrate to obtain herbimycin A (1) in 30 steps 
with an overall yield of 1.5 %. 
 
 
 
Reagents and conditions: a) i) Cl3CONCO, K2CO3, MeOH; ii) CAN (36 % over two steps). 
Scheme 44 
 
In her synthesis, Cossy obtained the C5-C15 fragment via a concise and efficient 
route when compared with the synthesis of the same fragment reported by Tatsuta
40
.  
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VI. Ardisson’s partial synthesis 
Ardisson and his team reported the construction of the three C16-N22 (154),  
C1-C7 (156) and C8-C15 (155) segments of herbimycin A (1) in an attempt to develop 
its convergent synthesis (Scheme 45).  
 
The key steps developed in this synthesis are an asymmetric Sharpless 
epoxidation
84,85
 and a diastereoselective Hoppe crotylation
86
 leading to fragment (155). 
 
 
 
Scheme 45 
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The synthesis of the C1-C7 fragment began with the conversion of dibromide 
(158) to the silyl ether (159) in three steps in an overall yield of 45 % (Scheme 46). 
Based on Shen’s methodology87, enyne (161) was formed by reacting (159) and (160) 
with dichloro bis-acetonitrile palladium (Pd(CH3CN)2Cl2), copper (I) iodide and 
diisopropylethylamine in dimethylformamide at 85 °C, to give the desired enyne (161) 
in a 63 % yield. 
 
Reagents and conditions: Pd(CH3CN)2Cl2 (15 mol %), CuI (30 mol %), (1.5 eq), DMF, 85 °C, 63 %. 
Scheme 46 
 
The C8-C15 fragment was formed starting with alcohol (125), which was turned 
into aldehyde (162) in six steps in a 50 % yield (Scheme 47). The aldehyde (162) 
subsequently underwent a Hoppe crotylation resulting in alcohol (163) in an 85 % yield 
as a single diastereoisomer. Alcohol (163) was then converted to alkyne (164) in three 
steps in an overall yield of 22%. Sharpless epoxidation was then carried out on alkene 
(164) which was treated with D-(-)-diethyltartrate to give (165) in an 85 % yield as a 
single diastereoisomer. The synthesis of the C8-C15 fragment ended up with two 
additional steps to yield alkyne (166) in an overall yield of 42 %. 
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Reagents and conditions: a) (E)-crotyl (diisopropyl)carbamate (2.6 eq), 1.6 M n-BuLi (2.4 eq),  
(-)-sparteine (2.3 eq), -78 °C, then Ti(Oi-Pr)4 (6 eq), pentane, -50 °C to -78 °C, then (162), 85 %;  
b) D-(-)-diethyl tartrate (1.2 eq), TBHP (2 eq), CH2Cl2, -25 °C, 85 %. 
Scheme 47 
 
The aromatic sub-unit (154) was formed in three steps from the commercially 
available di-iodo compound (167) in an overall yield of 55 % (Scheme 48). 
 
 
Reagents and conditions: a) NaNO2, HOAc, 80 °C, 80 %; b) m-CPBA, CH2Cl2, 4 °C, 80 %; 
 c) KOH, MeI, 20 °C, 85 %. 
Scheme 48 
 
 To the best of our knowledge, the coupling of fragments (154), (155) and (156) 
has not been reported yet. 
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VII. Micalizio’s partial synthesis 
Micalizio and his team developed a general convergent route
88
 to the C5 –C15 
subunits of the ansamycin antibiotics herbimycin A (1), geldanamycin (5) and macbecin 
1 (10). The key step in this synthesis would be the mediated coupling of alkyne (170) 
with aldehyde (171) (Scheme 49). 
 
Scheme 49 
 
Roche iodide (172)
89
 was first coupled to amide (173) based on Myers’ 
alkylation
90
 followed by the cleavage of the chiral auxiliary agent. Alcohol (174) was 
obtained in a 70 % yield (Scheme 50). Two additional steps lead to alkyne (170) in an 
overall yield of 50 %. 
 
 
Reagents and conditions: a) LDA, THF, -78 °C to rt.; b) BH3·NH3, LDA, THF, (70 % over two steps), 
(dr = 4:1). 
Scheme 50 
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A stereoselective titanium mediated coupling reaction between alkyne (170) and 
aldehyde (171) using ClTi(Oi-Pr)3 provided the C5-C15 fragment of herbimycin A (1) 
(Scheme 51). Alcohol (172) was thus obtained in a 58 % yield as the major isomer in a 
5:1 ratio of regioisomers and a 3:1 ratio of diastereoisomers in favour of the C7 
undesired diastereoisomer
91
. Oxidation of alcohol (172) to the ketone using Dess-Martin 
periodinane
92
 was followed by a stereo-selective reduction using L-selectride
93
 to give 
the desired C7 diastereo-isomer required for herbimycin A (1) corresponding to the C5-
C15 fragment (173) as the major diastereoisomer in an 84 % yield and a 20:1 ratio of 
diastereoisomers with regards to the C7 position (Scheme 51). 
 
 
Reagents and conditions: a) NaH, MeI, THF then ClTi(Oi-Pr)3, c-C5H9MgCl -78 to -30 °C, then -78 °C, 
BF3·OEt2, (171), 58 %, (dr = 3:1, (172:173)); b) Dess-Martin periodinane, CH2Cl2; b) L-Selectride, 84 % 
over two steps, (dr = 20:1, (173:172)) 
Scheme 51 
 
The advantage of the route Micalizio developed is that it can also be applied to 
the synthesis of geldanamycin (5) and macbecin 1 (10). 
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CHAPTER 3 
 
RESULTS AND DISCUSSION 
 
 
 
 75 
 
I. Previous Parsons’group study 
 
Dr. Ansell
94
, a former member in the Parsons group, worked on the total 
synthesis of herbimycin A (1). His study led to a concise, novel and divergent route to 
the advanced intermediate (174). 
The route proposed was to assemble the C11 and C12 stereo-centres as the last 
step in the macrocyclic assembly, using Pedersen’s method95. 
 
 
Scheme 52 
 
This advanced intermediate was derived from the coupling of an aromatic (175) 
and an aliphatic fragment (177) whose retrosynthesis is presented below.  
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Scheme 53 – Ansell’s retrosynthetic analysis 
 
With intermediate (174) in hand, Ansell converted it to the di-aldehyde (181) 
with the aim of achieving macro-cyclisation with (VCl3(THF)3), in conjunction with 
activated zinc dust based on Pedersen’s protocol95. Unfortunately, this did not proceed to 
give the desired product.  
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Reagents and conditions: VCl3(THF)3, Zn, THF, rt. 
Scheme 54 – Mc Murry approach 
 
This work was continued by Dr. Inga Pietsch
96
 who further studied the Pedersen 
coupling, without success, and also worked on alternative approaches, such as the Mc 
Murry coupling
97
 which uses a low valent titanium species, and the Stetter approach
98
 
with the macrocyclisation of the di-aldehyde (181). 
However, neither of these reactions resulted in the formation of the desired C11-
C12 bond. 
 
 
Reagents and conditions: (185), DBU, t-BuOH, 40 ºC. 
Scheme 55 - Stetter approach 
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The final attempt was attempted via RCM of the dialkene followed by selective 
dihydroxylation
99
 and succeeded in producing the C11-C12 bond, but the desired diol 
(188) could not be installed. 
 
 
Reagents and conditions: a) Grubbs II
nd
 generation catalyst, 10 mol %, CH2Cl2, approx. 43 %; b) OsO4, 
K2CO3, K3Fe(CN)6, (DHQ)2-Phal. 
Scheme 56 – RCM and dihydroxylation approach 
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II. Retrosynthetic analysis 
 
In this thesis, a brand new approach to herbimycin A (1), was envisaged in a 
mostly linear way. The first disconnection would be the amide bond, at the C1 position, 
whose coupling had been previously studied by Tatsuta
40,41
. 
 
 
Scheme 57 
 
A further series of disconnections then divided herbimycin A into two fragments: 
one an aliphatic (191) and the other a tetra substituted aromatic (190). 
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Scheme 58 
 
The lactone fragment (191) would be obtained via the oxidative lactonization of 
the primary carboxylic acid (192). This key step will be important in setting up the 
desired chirality in the final molecule. 
 
 
Scheme 59 
 
The primary acid (192) could be derived from the propionate (193) via an 
Ireland-Claisen rearrangement
100,101,102
. 
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Scheme 60 
 
Propionate (193) would be obtained from aldehyde (194) after a two steps, which 
itself would be the result of an oxidation and deprotection of alcohol (195). The 
E/Z-diene system could be achieved through a ring expansion
103
 of furyl alcohol (196). 
This alcohol (196) is chiral and could be installed following a procedure devised by 
Terashima
104
 starting from the corresponding furyl ketone. The E-olefin (198) would be 
the result of a Wittig reaction from aldehyde (199), with the ultimate starting material 
being the commercially available Roche’s ester (125). This ester had been used 
previously by Cossy
72
 and provides a starting point as it bears the desired C10 chiral 
center.   
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III. Initial attempt toward the aliphatic lactone fragment (191) 
 
The synthesis of the aliphatic fragment commenced with following the 
procedures developed by Drs. Ansell
94
 and Pietsch
96
. 
 
The initial step of the synthesis was to protect the alcohol of the chiral ester (125) 
using a silicon group in order to manipulate the ester. 
 
 
Reagents and conditions: TBSCl, imidazole, DMAP (7%), CH2Cl2, 95%. 
Scheme 61 
 
Initially, it was attempted to obtain the aldehyde (199) directly from the ester by 
the use of DIBAL, however, despite using only one equivalent of DIBAL, the best yield 
obtained was only 60 % (Scheme 62).  
 
 
Reagents and conditions: DIBAL-H (1 eq), CH2Cl2, -78˚C, 60%. 
Scheme 62 
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It was therefore thought more efficient to reduce to the alcohol and subsequently 
oxidize back up to the aldehyde (199). Extra equivalents of DIBAL were then used to 
give alcohol (201) in a 90 % yield (Scheme 63).  
 
 
Reagents and conditions: DIBAL-H, CH2Cl2, -78˚C, 90%. 
Scheme 63 
 
This was followed by oxidation to the aldehyde (199), obtained in an 85 % yield 
applying Parikh-Doering’s conditions105, using sulfur trioxide pyridine complex in 
dichloromethane and dimethyl sulfoxide. 
 
 
Reagents and conditions: SO3
.
Py, DMSO, CH2Cl2, Et3N, 85%.  
Scheme 64 
 
The ylide, 1-carboethoxy ethylidenetriphenylphosphorane was freshly prepared 
from ethyl 2-bromopropanoate in toluene. The reaction mixture was stirred at 60˚C for 
four hours. It was important not to go over 60˚C as beyond that temperature, the reaction 
mixture became viscous and the intermediate bromide salt was not obtained  
(Scheme 65). 
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Reagents and conditions: a) PPh3, Tol., 60˚C; b) 1M NaOH, CH2Cl2, 70%. 
Scheme 65 
 
This ylide (203) was then used to insert the E-double bond thanks to a Wittig 
reaction, leading to ester (198) in an 80% yield (Scheme 66). 
 
 
Reagents and conditions: Ph3P=C(Me)CO2Et, Tol., 60˚C, 80%. 
Scheme 66 
 
The next step consisted in reaching Weinreb amide
106,107
 (204). The main 
advantage in using a Weinreb amide is that over addition of organometallic reagents can 
be avoided.  The major advantage of this method over addition of organometallic 
reagents to more typical acyl compounds is that it avoids the common problem of over-
addition.  (204) had then to be formed in order to only have a single addition of 
furyllithium to obtain furylketone (205). 
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Reagents and conditions: (MeO)NH(Me).HCl, i-PrMgCl, THF, -5˚C, 4 h, 70%. 
Scheme 67 
 
Ester (198) was converted to Weinreb amide (204) in a 70 % yield with recovery 
of the starting material (198) which could then be used again. 
 
 
The following step was the addition of furyllithium, which was freshly prepared, 
to give furyl ketone (205) in a 95 % yield (Scheme 68). 
 
 
Reagents and conditions: furan, n-BuLi, THF, 0˚C, then -5˚C, 95%. 
Scheme 68 
 
 The following step was the reduction of the furyl ketone (205) to the alcohol 
(196), following the procedure developed by Terashima and his team
104,108
 (Scheme 69). 
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Reagents and conditions: LiAlH4, Et2O, (
_
)-N-methylphedrine, reflux, then N-ethylaniline, reflux,  
then -100˚C, 60%. 
Scheme 69 
 
Terashima discovered that a chiral reducing agent could be prepared from 
lithium aluminium hydride by reacting it with (-)-N-methylephedrine and N-ethylaniline. 
This was formed successfully to convert unsaturated ketones to their corresponding 
alcohols in high optical purity (78 % to 98 % ee) and high yields (92 % to 100 %).  
 
Terashima showed that the reduction using (-)-N-methylephedrine favoured the 
formation of the S-enantiomer.  
 
 Presented below is one of the most likely transition states the authors proposed. 
The ketone comes in from the upper face of the complex from the least hindered angle 
of approach.  
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where R1 = alkyl or H 
and R2 = alkyl or aryl 
 
Figure 17 - Transition state proposed by Terashima 
 
 
Following Terashima’s initial procedure, N-ethylaniline was then used, acting as 
the achiral amine additive (Scheme 69). The reducing agent was prepared just 
beforehand with lithium aluminium hydride which was first treated with 
(-)-N-methylephedrine at 0 ºC, followed by heating to reflux for 90 minutes. 
N-ethylaniline was then added and the reaction mixture was heated up again to reflux for 
a further 90 minutes. Before adding the furylketone (205), the reaction mixture was 
cooled down to about -100 °C. The reaction mixture was stirred at this same temperature 
for four hours, before being quenched. Subsequent work-up and purification led to furyl 
alcohol (196) in a 61% yield. 
 
Only later on did we found that Terashima
109
 obtained a better selectivity with 
the reduction of 4-phenyl-3(E)-buten-2-one (206) to the desired S-alcohol (S)-(-)-(207), 
using diphenylamine instead of N-ethylaniline. He also published a correction of his 
previous results. For instance, with the reduction of 4-phenyl-3(E)-buten-2-one (206), 
the optical purity obtained with N-ethylaniline was 47% with a yield of 94%. When 
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diphenylamine was employed, the optical purity reached 66% with a similar yield (97%) 
(Scheme 70). 
 
 
Reagents and conditions: a LiAlH4 (3.3 eq), (-)-N-methylphedrine (3.6 eq), N-ethylaniline (7.2 eq), 94%, 
47%, ee; b LiAlH4 (3.3 eq), (-)-N-methylphedrine (3.6 eq), diphenylamine (7.2 eq), 97%, 66%, ee. 
Scheme 70 - Reduction of 4-Phenyl-3-(E)-buten-2-one (206) by Terashima 
 
 
Next comes the formation of the lactol (195) through the ring expansion of the 
furyl compound (196) (Scheme 71). 
 
 
Reagents and conditions: NBS, THF/H2O (4:1), -5 °C, 62 %. 
Scheme 71 
 
Many reagents and conditions were tried by Ansell
94
, such as bromine
110
, 
dimethyldioxirane
111
, Sharpless
112
 and m-chloroperbenzoic acid
113
 but the best yields 
were obtained with the addition of a stoichiometric amount of  
N-bromosuccinimide at 0 °C in THF and water (4:1)
103
. Georgiadis and Couladouros
103
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stated several conditions in order to avoid the formation of any by-products and to reach 
high yields: 
- the temperature should be maintained below 5 °C, 
- any excess of N-bromosuccinimide had to be destroyed in order for the 
subsequently liberated in situ bromine to be immediately consumed. 
 
In order to remove any NBS and bromine residue, successive washings of the 
organic fraction were carried out with 15% aqueous sodium dithionite and 10% aqueous 
sodium bicarbonate. 
In addition, as our system proved to be acid-sensitive, neutral silica had to be 
used in order for the crude product to be purified by silica chromatography. Lactol (195) 
could be obtained in a 62% yield. 
 
Regarding the mechanism of this reaction, it was believed to proceed through the 
intermediates pictured below in Scheme 72. 
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Scheme 72 
 
The lactol (195) exists in equilibrium with its aldehyde form (208) thus allowing 
for reactions to take place with the carbonyl group (Scheme 73).  
 
 
Scheme 73 
 
Subsequent reaction of lactol (195) with Wittig ylide 1-carboethoxy 
ethylidenetriphenylphosphorane led to the desired E/Z-diene (209) in an 85% yield 
(Scheme 74). In order to prevent any isomerisation, the reaction was carried out at room 
temperature and neutral silica was used for the purification process. 
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Reagents and conditions: Ph3P=C(Me)CO2Et, C6H6, rt, 85 %. 
Scheme 74 
 
Then, the free secondary alcohol was protected with triisopropylsilyl
114
 (TIPS) in 
order to differentiate it from the primary alcohol which is being protected with 
terbutyldimethylsilyl. TIPS is one of the most sterically hindered silyl protecting groups. 
Reaction with tetrabutylammonium fluoride is a common method for TIPS 
desilylations
115
. Ogilvie and co-workers were the firsts to introduce the use of the 
triisopropylsilyl (TIPS) group as a selective protecting group for alcohols
116
. 
 
TIPS-protection reactions can be achieved using either triisopropylchlorosilane  
(TIPS-Cl), triisopropylsilane
117
 or the triflate
118
 (TIPS-OTf). According to Rucker
114
, the 
best results are obtained with TIPS-OTf which was therefore what was used for this 
specific step. 
The silylation of alcohol (209) led to the corresponding silyl ether (210) in an  
85 % yield. 
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Reagents and conditions: TIPSOTf, 2,6-lutidine, CH2Cl2, 0 °C, 85 %. 
Scheme 75 
 
As we were then in the presence of an enone, we decided to perform Luche 1,2-
reduction
119
 starting from enone (210) down to the corresponding chiral alcohol (211) in 
a 94% yield. A high level of stereoselectivity could be obtained but a minor by-product 
could also be observed by proton and carbon NMR. This by-product was thought to be a 
diastereoisomer. 
 
 
Reagents and conditions: CeCl3·7H2O, NaBH4, MeOH, 0 °C, 94%. 
Scheme 76 
 
Felkin-Ahn
120
 transition sate model can explain the observed diastereoselectivity. 
Below is presented the Felkin-Ahn transition state model (Scheme 77). 
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Scheme 77 
 
Scheme 77 above shows that the hydride is likely to attack from the less hindered 
face with an angle of 107 ˚C with regards to the carbonyl group. 
 
Alcohol (211) was then methylated using trimethyloxonium tetratfluoroborate 
and a proton sponge
TM
 to obtain the methyl ether (213) in an 89% yield (Scheme 78)
121
. 
 
 
Reagents and conditions: Me3OBF4, Proton Sponge
TM
, CH2Cl2, 89 %. 
Scheme 78 
 
 Now that we have finished working on the right hand-side of the molecule, we 
next turned our attention to the left hand-side. The idea was to selectively remove the 
TBS protecting group in the presence of the TIPS group as the latter one is bulkier and, 
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in our case, is connected to a secondary alcohol whereas the TBS group is only 
connected to a primary alcohol. 
 
In 1991, Marshall and co-workers reported the use of acetic acid to selectively 
deprotect TBS ethers in the presence of other protecting groups for the synthesis of the 
C11-C21 fragment of Macbecin 1
122
.  
 
 
Reagents and conditions: AcOH, THF, H2O, 87 %. 
Scheme 79 
 
The same conditions were used by Joullie
123
 for the synthesis of didemins A, B 
and C, in the presence of TIPS: 
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Reagents and conditions: AcOH, THF, H2O, 12 h, 83 %. 
Scheme 80 
 
Applying these same conditions to our substrate gave a successful result as the 
TBS group could be removed in a quantitative yield (Scheme 81). 
 
Reagents and conditions: AcOH, THF, H2O, overnight, 100 %. 
Scheme 81 
 
The deprotected primary alcohol (218) was then oxidized relying on Ley’s 
oxidation
124
 using TPAP and NMO, leading to the aldehyde (194) in a 70 % yield. 
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Reagents and conditions: NMO, TPAP, CH2Cl2, 70 %. 
Scheme 82 
 
Aldehyde (194) was then subjected to the attack of vinyl magnesium bromide, 
leading to allyl alcohol (219) in a 60 % yield (Scheme 83). Several spots were observed 
by thin layer chromatography, but only the ally alcohol (219) could be isolated after 
purification. Attack on the ester function of aldehyde (194) could explain why the yield 
is modest, although such by-product could not be isolated. 
 
  
Reagents and conditions: vinyl magnesium bromide, THF, 0˚C, 60 %. 
Scheme 83 
 
At this stage, we only had a small amount in hands to go ahead. So far, 15 steps 
have been carried out starting from Roche ester (125) with an overall yield of 3 %. Due 
to the lack of intermediate to proceed any further, we modified our route so that the 
Ireland-Claisen rearrangement could be performed at an earlier stage in the synthesis of 
the aliphatic fragment. 
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IV. Alternative Approach to the Aliphatic Fragment 
 
Below is shown our new retrosynthetic analysis: 
 
 
Scheme 84 
 
The main difference with our strategy is the aliphatic sub-units: 
 
 instead of  
Figure 18 
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We decided not to worry about the ring extension step and leave the furyl ring 
untouched. Our new target was then the aliphatic fragment (223) whose retrosynthesis is 
presented in Scheme 85 below. 
 
 
Scheme 85 
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The target lactone (221) would be formed from the acid (222). This acid (222) 
would be derived from the sigmatropic rearrangement of the propionate (223) using the 
Ireland-Claisen protocol. 
 
We hoped this propionate (223) could be synthesized from the already available 
alcohol (224) via protection of the secondary alcohol and manipulation of the protected 
primary alcohol (179). 
 
Therefore, we started again with chiral alcohol (179) which we could synthesize 
earlier and decided to protect it using the triisopropylsilyl group and different conditions 
were carried out: 
 
Entry Reagent Base Solvent Yield 
1 TIPS-OTf Et3N CH2Cl2 20 % 
2 TIPS-OTf 
i
Pr2NEt CH2Cl2 18 % 
3 TIPS-OTf 2,6-lutidine CH2Cl2 40 % 
4 TIPS-OTf 2,6-lutidine benzene 32 % 
Table 5 
 
On Table 5 above, the highest yield was obtained in CH2Cl2 using 2,6-lutidine. 
The alcohol (179) was taken up in dichloromethane and the temperature was cooled 
down to 0 °C before adding 2,6-lutidine. The reactive mixture was then stirred at 0 °C 
for about ten minutes and tri-isopropylsilyl trifluoromethanesulfonate added dropwise. 
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The reactive mixture was warmed up to ambient temperature and stirred overnight to 
produce, after work up and purification, the disilylated compound (225) in a 40 % yield 
(Scheme 86). 
 
 
Reagents and conditions: TIPS-OTf, 2,6-lutidine, CH2Cl2, 0 °C, 40 %. 
Scheme 86 
 
 
Attempts were made to selectively remove the TBS protecting group in the 
presence of the TIPS group. 
 
 
Scheme 87 
 
As the TIPS group being bulky and connected to a secondary alcohol compared 
to the TBS group connected to a primary alcohol, we thought the deprotection step 
would work. Acid hydrolysis, using 1% HC1 in ethanol, along with base hydrolysis, 
using 5% NaOH in ethanol, and fluoride cleavage, using TBAF in THF, did not work. 
The conditions applied earlier with a mixture of glacial acetic acid, water and THF did 
not work either. 
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Unfortunately, the reaction did not proceed for our substrate (226). The reaction 
was carried out with a scope of different acetic acid / water / THF ratios, without any 
positive outcome. We ended up getting a mixture of compounds which could not be 
separated nor characterized. 
 
We then had to change our strategy and decided to start from furyl ketone (205) 
(Scheme 88). 
 
Scheme 88 
 
 The primary alcohol being protected, we then had to deprotect it, allowing us to 
perform further reactions. 
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Reagents and conditions: Py
.
Br3 (5 %), MeOH, rt, 3 hours, 80 %. 
Scheme 89 
 
A series of reagents were tried (HCl, TBAF, H2SO4) but the best yield was 
obtained using pyridinium tribromide. 
Recently, Jennings and co-workers
125
 discovered that a substoichiometric amount 
of pyridinium tribromide (Py.Br3) in methanol could chemoselectively deprotect primary 
TBS ethers in the presence of other protecting groups. 
5 mol % of pyridinium tribromide was added to a solution of the protected 
alcohol in methanol at a temperature of -20˚C. After 3 hours, the reaction went to 
completion and after purification, the free alcohol was obtained in an 80 % yield. 
 
The mechanism the authors proposed is shown in Scheme 90.  
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Scheme 90 
 
Jennings assumed that pyridinium tribromide provides a small amount of HBr, 
and enters into a catalytic process. Along with the formation of HBr, protonation of the 
TBS ether should provide the oxonium cation, followed by a nucleophilic displacement 
with MeOH, thus cleaving the silyl ether and furnishing the desired alcohol. Final 
deprotonation of the secondary oxonium cation regenerates the acid catalyst, thus 
making the protocol catalytic in HBr. 
 
Moreover, the authors observed that pyridinium tribromide could selectively 
deprotect a primary TBS in the presence of TIPS as shown below: 
 
 
Reagents and conditions: 5 % Py.Br3, MeOH, 87 % 
Scheme 91 
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We then went back to our issue dealing with the selective deprotection of TBS in 
the presence of TIPS on our substrate (225). The same conditions as those in Scheme 91 
were attempted but once again, without a positive outcome. 
 
  
Reagents and conditions: 5 % Py.Br3, MeOH, 0 %. 
Scheme 92 
 
Therefore, we moved on to the oxidation of alcohol (227) to the aldehyde (231).  
 
 
 
Scheme 93 
 
A variety of common oxidizing reagents were employed (Table 10), including: 
pyridinium dichromate (PDC)
126
, (2,2,6,6-tetramethylpiperidin-1-yl) 
oxidanyl  (TEMPO)
127
, 2-iodoxybenzoic acid (IBX)
128
 and tetrapropylammonium 
perruthenate (TPAP)
124
. Unfortunately, all those reactions did not proceed with the 
exception of Ley’s oxidation where an aldehyde peak could be observed on the proton 
NMR, but in a very low ratio. 
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The use of Parikh-Doering conditions
105
 did lead to the aldehyde (231) but in a 
modest yield (Entry 7, Table 7). 
 
The best result was obtained by using Dess Martin periodinane (DMP)
128
 which 
proved to be the best reagent. In addition, the purification was much simplified in 
comparison to the Parikh-Doering reaction as there is no dimethyl sulfide involved. 
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Entry oxidizing agent Solvent Yield (%) 
1 PDC CH2Cl2 SM 
2 TEMPO, NaCl, KBr CH2Cl2 SM 
3 IBX Acetone SM 
4 IBX EtOAc SM 
5 IBX CHCl3 SM 
6 TPAP, NMO CH2Cl2 traces 
7 Py.SO3, NEt3, DMSO (rt) CH2Cl2 50 
7 Py.SO3, NEt3, DMSO (30˚C) CH2Cl2 50 
8 DMP CH2Cl2 67 
Table 6 
  
With aldehyde (231) in hand, a Grignard
129
 reaction using vinyl magnesium 
bromide allowed us to obtain allylic alcohol (232) in a 60 % yield when 1 equivalent of  
the Grignard reagent was used. 1.2 equivalents was also used and the reaction was 
quenched after 4 hours as we feared the Grignard reagent could have attacked different 
electrophilic centres (Figure 19). Either way, the starting aldehyde (231) that did not 
react could still be recovered and used again. 
 
 
Figure 19
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Entry Conditions Eq. Time Solvent Yield (%) 
1 CH2=CHMgBr 1.2 4 hours THF 55 
2 CH2=CHMgBr 1 4 hours THF 53 
3 CH2=CHMgBr 1 18 hours THF 60 
Scheme 94 & Table 7 
 
The addition of vinylmagnesium bromide was not diastereoselective as the 
presence of diastereoisomers could be observed in the NMR spectra. Separation could 
not be achieved. 
 
 Allylic propionate (233) was formed by reaction of alcohol (232) with  
propionyl chloride at 0˚C with 2,6-lutidine as a base (Scheme 95).  
 
 
Reagents and conditions: propionyl chloride, 2,6-lutidine, CH2Cl2, 0˚C, 89 %. 
Scheme 95 
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The stereoselective reduction of the ketone was conducted using Terashima’s 
conditions were carried out, but the main difference with our substrate is that two 
carbonyl groups are present. Therefore, only 1 equivalent of the reducing agent was 
used, and the proportions of the other reagents where altered accordingly. Alcohol (234) 
was obtained in a 71% yield. With this reaction, we were expecting to obtain a mixture 
of diastereoisomers, which unfortunately could not be separated. 
 
 
Reagents and conditions: LiAlH4, Et2O, (
_
)-N-methylphedrine, reflux, then N-ethylaniline, 
 reflux, then -100˚C, 71%. 
Scheme 96 
 
 We were then ready to investigate the Ireland-Claisen rearrangement
130
 starting 
from allylic propionate (234). 
 
 
Reagents and conditions: DMPU, LiHMDS, TMSCl, THF, 0˚C. 
Scheme 97 
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The Ireland-Claisen rearrangement refers to the [3,3] rearrangement of allylic 
esters (236) as ester enolates (237) to give α,β-unsaturated carboxylic acids (238)  
(Scheme 98). 
 
 
Scheme 98 – Ireland-Claisen rearrangement 
 
Regarding the geometry of the products of the Ireland-Claisen rearrangement, it 
can be predicted by looking at the stereochemistry of the double bonds involved in the 
ketene acetal rearragenment. The (E)-enolate (239a) predominantly gives an erythro 
product (241), whereas the (Z)-enolate one (239b) gives a threo compound (243) as the 
main product (Scheme 99). Ireland suggested the rearrangement proceeds through a four 
centered “chair-like” transition state, as shown below, thus allowing stereo-selection of 
the products
131
. 
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Scheme 99 
 
The geometry of the silyl ketene acetal can be controlled during the ester 
enolization step by varying the solvent system. The formation of the (Z)-enolates is 
favored by THF as the solvent, whereas using an HMPA/THF combination favors the 
formation of the (E)-enolate (lithium enolate). Depicted in Figure 20 below are the two 
competing pericyclic, six-membered chair-like transition states (I and II) for the 
deprotonation step. Transition state I (244), leading to the Z-enolate, would be 
destabilized by an unfavorable 1,2-interaction between R and OR’. On the other hand, 
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transition state II (245), the one leading to the E-enolate, would be destabilized by an 
unfavorable 1,3-diaxial interaction between R and the axial isopropyl group of the base.  
In the absence of HMPA, the 1,3-diaxial interactions predominate. In the presence of 
HMPA, the 1,2-interactions predominate, which may be rationalized by the assumption 
that the lithium-enolate oxygen distance is increased due to the decreased Lewis acidity 
of the lithium cation in the presence of external Lewis basic ligands, like HMPA. A 
looser cyclic transition state would weaken the transannular interactions and the 1,2-
interactions are more important (Figure 20). 
 
 
Figure 20 
 
In addition, the stereochemistry of the allylic bond (cis or trans) is retained on 
silylation and both compounds predominantly give the erythro and the threo isomers on 
rearrangement (Scheme 100).  
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Scheme 100 
 
In our case, there is no substituent on the initial double bond. Also, we have to 
pay attention to the stereo-chemistry of C14 of hebimycin A (Scheme 21). 
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Scheme 101 
 
We were interested in getting the S enantiomer through this rearrangement. 
Therefore, we need to go through the (E)-silyl enol ether, thus using a coordinating 
solvent, such as DMPU and HMPA, during the reaction. 
 
 Different conditions, described in Table 12, were tried. Due to the toxicity of 
HMPA, DMPU was first used as the coordinating solvent. Different trapping agents 
(TMSCl and TBSCl) and bases (LHMDS, LDA) were also used, without any success 
(entry 1-5). 
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Entry Base Solvent 
Trapping 
agent 
Temperature (˚C) Yield (%) 
1 LHMDS THF/DMPU TMSCl -78˚ to rt decomp. 
2 LHMDS THF/DMPU TMSCl -78 to 50 decomp. 
3 LHMDS THF/DMPU TBSCl -78 to rt/50 decomp. 
4 LDA THF/DMPU TMSCl -78 to rt/50 decomp. 
5 LDA THF/DMPU TBSCl -78 to rt/50 decomp. 
6 LDA THF/HMPA TBSCl -78 to rt silyl ester 
(247) (traces) 
Scheme 102 & Table 8 
 
 
Figure 21 
 
However, Giroux and Corey
132
 have recently developed a pathway for the stereo-
controlled elaboration of dafachronic A. Reaction of allylic propionate (248) with LDA 
in THF-HMPA at -78 °C produced an enol silyl ether which without isolation was heated 
at reflux to undergo a highly stereo-selective Ireland-Claisen rearrangement, yielding 
acid (249) (Scheme 102). 
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Reagents and conditions: LDA, TBSCl, THF-HMPA, -78˚C to rt, 7 h, 66 %. 
Scheme 103 
 
 We therefore tried the same conditions on our substrate (234) (Table 12,  
Entry 6). However, we noticed that the silyl group was not removed. Indeed, the mixture 
was only warmed up to room temperature.  
 
 
Scheme 104 
  
The next logical step was then to perform the reaction again with the same 
conditions with heating the reaction mixture. However, due to the lack of intermediate, 
this step could not be carried out.  
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V. Attempts toward the Aromatic Fragment 
 
Our target was the aromatic sub-unit (190) presented in Scheme 105 below along 
with our retrosynthetic route. This advanced aromatic fragment (190) would be obtained 
starting from commercially available 4-methoxyphenol (252) that would undergo 
successive nitration, bromination and methylation. The nitro group would then be 
reduced to the amine which could then be modified. 
 
 
Scheme 105 
 
 Previously in the Parsons’ group, Ansell94 successfully converted aniline (253) 
into trifluoroacetamide (254)
133
.  
 
 
Reagents and conditions: TFAA, Et3N, CH2Cl2, 0˚C, 92%. 
Scheme 106 
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Ansell obtained the aniline fragment starting with commercially available  
2-hydroxy-5-methoxybenzaldehyde which was successively nitrated and methylated. 
Aldehyde (255) was then subjected to Brown’s crotylation134 to insert the C14-C15 
stereocentres in a single step (Scheme 106).  
 
 
Reagents and conditions: a) HNO3, AcOH, 10°C to 20 °C, 61 %; b) MeI, Ag2O, CHCl3, 40 °C, 64 %; 
c) H2O2, 3 M NaOH, 89 %; d) MeI, NaH, THF, 0 °C, 90 %; e) conc. HCl, Sn, EtOH, 98 %. 
Scheme 107 
 
 We then decided to protect our amine with the trifluoroacetamide group. 
Following Cossy’s procedure72, the synthesis of the aromatic fragment started with 
commercially available 4-methoxyphenol (252), which was nitrated using sodium nitrite 
and glacial acetic acid in ethanol. The reactive mixture was heated to reflux for 2 hours, 
leading to the nitro compound (260) in a 70 % yield (Scheme 107). 
 
 118 
 
Reagents and conditions: NaNO3, AcOH, EtOH, 54 %. 
Scheme 108 
 
 Regioselective ortho-bromination of the aromatic ring, followed by methylation 
using dimethylsulfate and potassium carbonate allowed us to obtain (251) in a 90 % yield 
(Scheme 108). 
 
 
Reagents and conditions: a) Br2, AcONa, AcOH, 76 %;  
b) Me2SO4, K2CO3, acetone, reflux, 90 %. 
Scheme 109 
 
The next step consisted in the selective reduction of the nitro group using iron 
powder and acetic acid in water (Scheme 110). 
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Reagents and conditions: Fe, AcOH, H2O, reflux, 86% 
Scheme 110 
 
The next logical step was then to turn the amine into trifluoroacetamide, but due 
to time constrains, this step could not be performed.  
 
 
 
Reagents and conditions: TFAA, Et3N, CH2Cl2, 0 °C 
Scheme 111 
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VI. Conclusion and future work 
 
To conclude, the route to herbimycin A (1) developed in this thesis proved to be 
very challenging as it had to be rethought several times. The synthesis was split into two 
parts, being the synthesis of the aromatic portion and the synthesis of the aliphatic 
fragment. The key step leading to the latter one, being the Ireland-Claisen rearrangement, 
seems to work although it still needs to be optimized. 
 
Once the Ireland-Claisen will have been optimized, the next step would be a 
lactonization, with the resulting alcohol being methylated. 
 
Reagents and conditions: a) AD mix , tBuOH, H2O; b) MeI, NaH, DMF, 0 °C. 
Scheme 112 
 
Then, the aromatic compound would be coupled with the aliphatic fragment, with 
once again the resulting alcohol being methylated. 
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Reagents and conditions: a) (190) n-BuLi, Et2O, -78 °C to rt, then -78 °C; b) MeI, NaH, DMF, 0 °C. 
Scheme 113 
 
The right hand side of the molecule would be allowed to go through a ring 
expansion, followed by a Wittig reaction in order to insert all the necessary carbon atoms. 
The following steps are similar to those carried out earlier on during the first route of the 
synthesis of herbimycin A (1) (Scheme 114). 
 
Reagents and conditions: a) NBS, THF/H2O (4:1), -5 °C; b) Ph3P=C(Me)CO2Et, C6H6, rt; 
c) TIPSOTf, 2,6-lutidine, CH2Cl2, 0 °C; d) CeCl3·7H2O, NaBH4, MeOH, 0 °C;  
e) Me3OBF4, Proton Sponge
TM
, CH2Cl2. 
Scheme 114 
 
The total synthesis would be achieved by performing an amide coupling, followed 
by silyl deprotection, carbamate formation and quinone formation to yield herbimycin A 
(1) (Scheme 115). 
 122 
 
 
Scheme 115 
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CHAPTER 4 
 
EXPERIMENTAL 
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I. General Experimental Detail 
 
Reactions requiring anhydrous conditions were conducted by using flame-dried 
glassware. 
Anhydrous Et2O and tetrahydrofuran were distilled from sodium in the presence of 
benzophenone. CH2Cl2, benzene, toluene, DMF, triethylamine, and ethyl acetate were 
distilled from calcium hydride prior to use. Methanol and ethanol were distilled from 
activated magnesium turnings using a crystal of iodine. All other grade solvents were 
used as received for routine purposes from Fischer scientific. Chemical reagents were 
commercially available, and used without further purification unless otherwise stated.   
All reactions were monitored, where appropriate, by analytical thin layer 
chromatography using Merck glass backed plates pre-coated with 0.25 mm layer of silica 
gel 60 F254 containing a fluorescent indicator. Visualisation was achieved with Ultra 
Violet florescence radiation (254 nm), and/or by staining with alkaline potassium 
permanganate, vanillin, or phosphomolybdic acid dips. Purification by flash column 
chromatography was carried according to Still’s procedure135 using Fisher Scientific 
silica 60A (35-70 mesh). 
1
H NMR spectra were recorded using a Varian VNMRS operating at 500 MHz. 
Samples were run at ambient probe temperature using CDCl3 as the solvent, unless 
otherwise stated. Residual isotopic solvent (CHCl3, δH = 7.27 ppm) was used as the 
internal reference. Chemical shifts (δ) are quoted in parts per million (ppm), and coupling 
constants (J) are measured in Hertz (Hz). The following abbreviations are used to 
describe the multiplicity of a given signal: s, singlet; d, doublet; t, triplet; m, multiplet; br, 
broad singlet; app, apparent.  
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13
C NMR spectra were recorded using a Varian VNMRS operating at 125 MHz. 
Samples were run at ambient probe temperature using CDCl3 as the solvent, unless 
otherwise stated. Residual isotopic solvent (CHCl3, δC = 77.00 ppm) was used as the 
internal reference. Chemical shifts (δ) are quoted in parts per million (ppm). Carbon 
spectra assignments are supported by DEPT and correlation experiments. 
The numbering of all the compounds mentioned in this section is arbitrary, with the 
sole intention to aid in the assignment of protons and carbons in the relevant spectra. As 
such, they do not necessarily correspond with that of the I.U.P.A.C. system. 
Infrared spectra (IR) were recorded on a Perkin-Elmer FT-IR 298 (1710) 
spectrometer, with absorption maxima (νmax) measured in cm
-1
. Some samples were 
prepared as either a thin film (liquids) or a solution in CH2Cl2 (solids) between sodium 
chloride plates, and other samples were directly placed on a universal attenuated total 
reflectance sampling accessory.      
Mass spectrometry data were recorded by Dr. Alaa Abdul-Sada on a Bruker 
Daltronics Apex III 4.7T using positive electro-spray ionization (+’ve ESI), and a Fisons 
Instrument VG Autospec using positive electron impact (+’ve EI), with methanol as the 
solvent. Only molecular ions, fractions from molecular ions and other major peaks are 
reported as mass/charge (m/z) ratios. The following abbreviations are used to describe the 
experiment: HRMS, high resolution mass spectrometry; LRMS, low resolution mass 
spectrometry. 
 
Optical rotations were recorded using a Bellingham-Stanley ADP440 polarimeter 
with a 1 cm-path length cell. Optical rotation [α]D data are given in units 10
-1
deg.cm
2
.g
-1
, 
and solution concentrations are given in g/100 cm
-3
.  
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II. Experimental Procedures 
 
 
Methyl (2R)-3-{[tert-butyl(dimethyl)silyl]oxy}-2-methylpropanoate (200) 
 
 
 
To a stirred solution of tert-butyldimethylsilyl chloride (15.0 g, 100 mmol) in 
CH2Cl2 (220 mL) under an atmosphere of nitrogen at 0 °C, was added imidazole (6.8 g, 
100 mmol) as a single portion. The resulting reaction mixture was stirred for five minutes 
and a solution of (R)-(3)-hydroxy-2-methylpropionate (200) (7.8 g, 66 mmol) in CH2Cl2 
(50 mL) was added drop wise. The reaction mixture was stirred for a further ten minutes 
and N,N-dimethylaminopyridine (0.8 g, 6.6 mmol) was added as a single solid portion. 
The reaction mixture was allowed to warm up to room temperature overnight and was 
then quenched with water (300 mL). The layers were separated and the aqueous phase 
was extracted with CH2Cl2 (4 x 100 mL). The organic phases were combined and dried 
over magnesium sulfate, filtered and the solvent was removed under reduced pressure. 
Purification by flash column chromatography (3 % Et2O : petroleum ether) yielded silyl 
ether (200) as a clear oil (14.5 g, 95 %).  
 
Rf 0.40 (2 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 3.73 (1 H, dd, J 7.0 Hz, 9.6 Hz, H-4), 3.63 (3 H, s, H-8), 
3.61-3.58 (1 H, m, H-4), 2.66-2.55 (1 H, m, H-5), 1.09 (3 H, d, J 7.2 Hz, H-6), 0.83 (9 H, 
s, H-1), -0.01 (6 H, s, H-3).  
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13
C NMR (125 MHz, CDCl3) δ 175.3 (C-7), 65.2 (C-4), 51.4 (C-8), 42.4 (C-5), 25.7 (C-
1), 18.1 (C-2), 13.4 (C-6), -5.6 (C-3). 
HRMS (ESI) m/z = 255.1374 (calc. 255.1387) C11H24O3SiNa [M + Na]. 
νmax (thin film)/cm
-1
 2955, 2931, 2886, 2859, 1744 (C=O), 1472, 1464, 1436. 
[α]D
28 
-20.2º (c 1.57 in CHCl3). 
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Methyl (2R)-3-{[tert-butyl(dimethyl)silyl]oxy}-2-methylpropanol (201) 
 
 
 
To a stirred solution of ester (200) (10.0 g, 43 mmol) in CH2Cl2 (250 mL) at -78 
°C under an atmosphere of nitrogen, was added diisobutylaluminium hydride  
(95 mL of a 1 M solution in CH2Cl2, 95 mmol) drop wise over four hours. The reaction 
mixture was allowed to warm up to room temperature overnight and was quenched with a 
cold solution of potassium sodium tartrate (54 g) and water (300 mL). The resulting 
cloudy solution was stirred until it became clear and the layers were separated. The 
aqueous phase was extracted with CH2Cl2 (3 x 150 mL). The organic layers were 
combined, dried over magnesium sulfate, filtered and the solvent was removed under 
reduced pressure to yield alcohol (201) as a clear oil. (8.3 g, 90 %). 
 
Rf 0.24 (20 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 3.74 (1 H, dd, J 4.1 Hz, 9.6 Hz, H-7), 3.65-3.58 (2 H, m, 
H-4), 3.54 (1 H, dd, J 7.8 Hz, 9.5 Hz, H-7), 2.0-1.88 (1 H, m, H-5), 0.89 (9 H, s, H-1), 
0.83 (3 H, d, J 6.8 Hz, H-6), 0.07 (6 H, s, H-3).  
13
C NMR (125 MHz, CDCl3) δ 68.5 (C-7), 67.9 (C-4), 37.0 (C-5), 25.8 (C-1), 18.1 (C-
2), 13.0 (C-6), -5.7 (C-3). 
HRMS (ESI) m/z = 227.1428 (calc. 227.1438) C10H24O2SiNa [M + Na]. 
νmax (thin film)/cm
-1
 3366 (br, OH), 2956, 2930, 2886, 2859, 1472, 1464, 1389, 1362, 
1256, 1091, 1040, 939, 837, 776, 667.  
[α]D
29 
-10.6º (c 1.70 in CHCl3). 
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Methyl (2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-methylpropanal (199) 
 
 
 
To a stirred solution of alcohol (201) (13.5 g, 67 mmol) in CH2Cl2 (275 mL) 
under an atmosphere of nitrogen, was added triethylamine (47.1 mL, 335 mmol) at  
0 °C. A solution of sulfurtrioxide pyridinium complex (42.6 g, 268 mmol) in 
dimethylsulfoxide (55 mL) was added drop wise over four hours. The resulting reaction 
mixture was allowed to warm up to room temperature overnight and was quenched with a 
saturated solution of aqueous ammonium chloride (100 mL). The layers were separated 
and the aqueous phase was extracted with Et2O (7 x 100 mL). The organic layers were 
combined, washed with a solution of saturated sodium chloride (100 mL), dried over 
magnesium sulfate, filtered and the solvent was removed under reduced pressure. 
Purification by flash column chromatography (5 % Et2O : petroleum ether) yielded 
aldehyde (199) as a pale yellow oil (11.5 g, 85 %) 
 
Rf 0.45 (8 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 9.72 (1H, d, J 1.5 Hz, H-7), 3.85 (1 H, dd, J 10.2 Hz,  
5.0 Hz, H-4), 3.80 (1 H, dd, J 10.1 Hz, 6.2 Hz, H-4), 2.57-2.46 (1 H, m, H-5), 1.07 (3 H, 
d,  J 6.9 H-6), 0.86 (9 H, s, H-1), 0.04 (6 H, s, H-3).  
13
C NMR (125 MHz, CDCl3) δ 204.7 (C-7), 63.4 (C-4), 48.8 (C-5), 25.7 (C-1), 18.2  
(C-2), 10.2 (C-6), -5.6 (C-3). 
LRMS (EI) m/z 203 ([M+H]+, 36 %), 185 (14), 161 (100), 133 (25), 75 (55). 
νmax (thin film)/cm
-1
 2957, 2931, 2885, 2859, 2713, 1736 (C=O), 1473, 1464, 1390, 
1362, 1256, 1099, 1033, 1007, 939, 838, 815, 777, 668, 342. 
[α]D
31 
-44.3º (c 1.98 in CHCl3). 
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1-carbo-ethoxyethylidenetriphenylphosphorane (203) 
 
 
 
Ethyl 2-bromopropanoate (14.9 mL, 115 mmol) was added drop wise to a stirred 
solution of triphenylphosphine (30.0 g, 115 mmol) in toluene (150 mL). The reaction 
mixture was heated at 60 °C and a white precipitate was formed. The mixture was then 
stirred for 4 hours and toluene was evaporated under vacuum. Et2O (200 mL) was then 
added to the crude mixture and left stirring vigorously for 2 hours. Filtration yielded the 
bromide salt as a white powder.  
The obtained salt was then dissolved in CH2Cl2 (200 mL) and 1M aq NaOH (115 
mL, 115 mmol) was added to the solution. The mixture was stirred for 20 minutes after 
which the organic phase was separated and the aqueous layer extracted with CH2Cl2  
(2 x 50ml). The combined organic extracts were dried on magnesium sulfate and 
concentrated under reduced pressure to give (203) as a light yellow powder (29.0 g,  
70 %). 
 
1
H NMR (500 MHz, CDCl3) δ 7.7-7.4 (15 H, m, H-1,2,3) 3.71 (2 H, q, H-7), 1.61 (3 H, 
d, H-5) 0.45 (3 H, t, H-8). 
νmax (thin film)/cm
-1
 1624, 1589, 1431, 1187, 1088. 
mp 157 °C (litt. 157-159) °C. 
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Ethyl (2E,4R)-5-{[tert-butyl(dimethyl)silyl]oxy}-2,4-dimethyl-2-pentenoate (198) 
 
 
 
To a stirred solution of phosphorane (203) (11.6 g, 32 mmol) in toluene (100 mL), 
was added a solution of aldehyde (199) (5.0 g, 25 mmol) in toluene (50 mL) at room 
temperature. The reaction mixture was then heated at reflux for thirty six hours and was 
subsequently allowed to cool down to room temperature. The solvent was removed under 
reduced pressure and the crude was taken up in hexane (100 mL). The resulting white 
precipitate was filtered off and the same process was repeated twice. The remaining 
solution was concentrated under reduced pressure and the crude material was purified by 
flash column chromatography (2 % Et2O : petroleum ether) to give alkene (198) as a 
colorless oil (5.4 g, 80 %). 
 
Rf 0.47 (15 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 6.55 (1 H, d, J 10.2 Hz, H-7), 4.23-4.11 (2 H, m, H-11), 
3.49 (2 H, d, J 6.0 Hz, H-4), 2.74-2.62 (1 H, m, H-5), 1.85 (3 H, s, H-9), 1.29 (3 H, t, 
J  7.2 Hz, H-12), 1.00 (3 H, d, J 6.6 Hz, H-6), 0.87 (9 H, s, H-1), 0.03 (6 H, s, H-3). 
13
C NMR (125 MHz, CDCl3) δ 168.1 (C-10), 144.4 (C-7), 127.8 (C-8), 67.0 (C-4), 60.3 
(C-11), 36.2 (C-5), 25.8 (C-1), 18.9 (C-2), 16.1 (C-6), 14.2 (C-12), 12.6 (C-9), -5.5 (C-3). 
HRMS (ESI) m/z = 309.1828 (calc. 309.1856) C15H30O3SiNa [M + Na]. 
νmax (thin film)/cm
-1
 2956, 2928, 2857, 1711 (C=O), 1468, 1234, 1085, 832. 
[α]D
25.5 
-4.5º (c 1.79 in CHCl3). 
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(2E,4R)-5-{[tert-butyl(dimethyl)silyl]oxy}-N-methoxy-N-2,4-trimethyl-2-
pentenoamide (204) 
 
 
 
To a stirred solution of ester (198) (4.1 g, 15 mmol) in tetrahydrofuran (150 mL) 
was added N,O-dimethylhydroxylamine hydrochloride (2.2 g, 22.5 mmol) as a single 
solid portion at room temperature under a nitrogen atmosphere. The reaction mixture was 
cooled to -20 °C and iso-propylmagnesium chloride (22 mL of a 2.0 M solution in 
tetrahydrofuran, 44 mmol) was added drop wise ensuring that the temperature remained 
below -5 °C. The reaction mixture was stirred at -5 °C (methanol and ice bath) for four 
hours, before being quenched by a solution of saturated aqueous ammonium chloride 
(100 mL). The layers were then separated and the aqueous phase was extracted with Et2O 
(2 x 50 mL). The combined organic extracts were dried over magnesium sulfate, filtered 
and the solvent was removed under reduced pressure. The crude was purified by flash 
column chromatography (35 % Et2O : petroleum ether) and the Weinreb amide (204) was 
obtained as a yellow oil (3.2 g, 70 %). 
 
Rf 0.26 (40 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 5.62 (1H, d, J 7.9 Hz, H-7), 3.64 (3 H, s, H-11), 3.53-
3.42 (2 H, m, H-4), 3.22 (3 H, s, H-12), 2.68-2.59 (1 H, m, H-5), 1.88 (3 H, s, H-9), 0.99 
(3 H, d, J 6.6 Hz, H-6), 0.88 (9 H, s, H-1), 0.03 (6 H, s, H-3).  
13
C NMR (125 MHz, CDCl3) δ 172.6 (C-10), 136.2 (C-7), 131.0 (C-8), 67.3 (C-4), 60.8 
(C-11), 35.4 (C-12), 33.9 (C-5), 25.9 (C-1), 18.3 (C-2), 16.5 (C-6), 14.1 (C-9), -5.4 (C-3). 
HRMS (ESI) m/z = 302.2136 (calc. 302.2146) C15H32O3NSi [M + H]. 
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νmax (thin film)/cm
-1
 2957, 2930, 2896, 2858, 1741, 1655 (C=O), 1460, 1363, 1257, 
1098, 1028, 1007, 837, 777, 666. 
[α]D
26 
-5.5º (c 1.74 in CHCl3). 
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(2E,4R)-5-{[tert-butyl(dimethyl)silyl]oxy}-1-(2-furyl)-2,4-dimethyl-2-penten-1-one 
(205) 
 
 
 
To a stirred solution of furan (3.80 mL, 52 mmol) in tetrahydrofuran (100 mL) at 
-78 °C under an atmosphere of nitrogen was added n-butyllithium (20.8 mL of a 2.5 M 
solution in hexanes, 52 mmol) drop wise. The reaction mixture was allowed to warm up 
to -5 °C over four hours. The resultant yellow solution of 2-furyl-lithium was added drop 
wise to a stirred solution of Weinreb amide (204) (10.5 g, 35 mmol) in tetrahydrofuran 
(500 mL) at 0 °C under an atmosphere of nitrogen over thirty minutes. The reaction 
mixture was stirred overnight at room temperature, before being quenched by pouring 
into an iced cooled solution of saturated aqueous ammonium chloride (300 mL). The 
layers were separated and the aqueous phase extracted with Et2O (3 x 250 mL). The 
combined organic extracts were dried over magnesium sulfate, filtered and the solvent 
was removed under reduced pressure. The crude material was purified by flash column 
chromatography (10 % Et2O : petroleum ether) and furyl ketone (205) was isolated as a 
yellow oil (10.0 g, 95 %). 
 
Rf 0.54 (20 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 7.59-7.58 (1H, m, H-14), 7.03 (1H, d, J 3.6 Hz, H-12), 
6.48-6.46 (1H, m, H-13), 6.42 (1H, d, J 9.6 Hz, H-7), 3.59-3.49 (2H, m, H-4), 2.83-2.74 
(1H, m, H-5), 1.94 (3H, s, H-9), 1.02 (3H, d, J 6.8 Hz, H-6), 0.86 (9H, s, H-1), 0.02 (6H, 
s, H-3). 
13
C NMR (125 MHz, CDCl3) δ 185.1 (C-10), 151.8 (C-11), 146.5 (C-14), 145.8 (C-13), 
135.6 (C-8), 119.4 (C-12), 111.5 (C-7), 67.1 (C-4), 36.4 (C-5), 25.8 (C-1), 18.2 (C-2), 
16.1 (C-6), 12.8 (C-9), -5.5 (C-3). 
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HRMS (ESI) m/z = 331.1696 (calc. 331.1670) C17H28O3SiNa [M + Na]. 
νmax (thin film)/cm
-1
 2930, 1648 (C=O), 1561, 1467, 1389, 1297, 1253, 1091, 1031, 837, 
776, 666. 
[α]D
28 
-12.3º (c 2.21 in CHCl3). 
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5-(tert-Butyl-dimethyl-silanyloxy)-1-furan-2-yl-2,4-dimethyl-pent-2-en-1-ol (196) 
 
 
 
(1R),(2S)-(-)-N-methylephedrine (4.0 g, 22.1 mmol) in Et2O (60 mL) was added 
drop wise to a stirred solution of lithium aluminium hydride (820 mg, 21.5 mmol) in 
Et2O (20 mL) at 0 °C under an atmosphere of nitrogen. The reaction mixture was heated 
to reflux for two hours, before being allowed to cool to room temperature. A solution of 
freshly distilled N-ethylaniline (5.7 mL, 45.5 mmol) in Et2O (20 mL) was added drop 
wise and the reaction mixture was heated to reflux for a further two hours. The reaction 
mixture was cooled to -100 °C and a solution of furyl ketone (205) (2.0 g, 6.5 mmol) in 
Et2O was added drop wise. The reaction mixture was stirred at -100 °C for four hours, 
before subsequently being quenched by pouring into an ice cooled aqueous solution of 
sodium potassium tartrate (16.0 g) and water (150 mL). The solution was allowed to 
warm to room temperature overnight. The layers were separated and the aqueous phase 
was extracted with Et2O (3 x 100 mL). The combined organic extracts were washed with 
a solution of saturated aqueous copper sulfate (100 mL), a solution of saturated aqueous 
sodium chloride (2 x 100 mL) dried over magnesium sulfate, filtered and the solvent was 
removed under reduced pressure. The crude material was purified by flash column 
chromatography (3 % Et2O : petroleum ether) and furyl alcohol (196) was isolated as a 
yellow oil (1.23 g, 60 %). 
 
Rf 0.21 (20 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 7.37 (1H, s, H-14), 6.33 (1H, s, H-12), 6.23 (1H, s,  
H-13), 5.40 (1H, d, J 10 Hz, H-7), 5.11 (1H, s, H-10), 3.52-3.41 (2H, m, H-4), 2.65-2.60 
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(1H, m, H-5), 1.66 (3H, s, H-9), 1.23 (1H, br, OH), 1.00 (3H, d, J 10 Hz, H-6), 0.90 (9H, 
s, H-1), 0.04 (6H, s, H-3). 
13
C NMR (125 MHz, CDCl3) δ 155 (C-11), 142 (C-14), 134 (C-8), 130 (C-13), 110  
(C-12), 106 (C-7), 73.2 (C-10), 67.7 (C-4), 35.3 (C-5), 25.9 (C-1), 18.3 (C-2), 17.2 (C-6), 
13.0 (C-9), 5.33 (C-3). 
HRMS (ESI) m/z = 333.1860 (calc. 333.1856) C17H30O3SiNa [M + Na]. 
νmax (thin film)/cm
-1
 3412 br (CHOH), 2929, 2857, 1472, 1388, 1256, 1088, 1007, 836, 
776, 734, 666. 
[α]D
28 
+4.69º (c 1.28 in CHCl3). 
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(S)-2-((S,E)-5-(t-Butyldimethylsilyloxy)-4-methylpent-2-en-2-yl)-6-hydroxy-
2Hpyran-3(6H)-one (195) 
 
 
 
To a stirred solution of alcohol (196) (1.0 g, 3.23 mmol) in tetrahydrofuran  
(80 mL) and water (20 mL) was added N-bromosuccinimide (575 mg, 3.23 mmol) as a 
single portion at -5 °C under a nitrogen atmosphere. The dark yellow reaction mixture 
was stirred at the same temperature for one hour, before addition of a solution of 10 % 
aqueous potassium iodide (50 mL). The solution was allowed to warm to room 
temperature, the layers were then separated and the aqueous phase was extracted with 
Et2O (3 x 100 mL). The combined organic extracts were washed with a solution of 15 % 
aqueous sodium dithionite (100 mL), followed by a solution of 10 % aqueous sodium 
bicarbonate (100 mL). The organic extracts were dried over magnesium sulfate, filtered 
and most of the solvent was removed under reduced pressure. To avoid decomposition 1-
2 mL of solvent was retained. The crude material was purified by flash column 
chromatography using neutral silica (20 % Et2O : petroleum ether) and lactol (195) was 
isolated as a yellow oil  (653 mg, 62 %, 2 diastereoisomers with a 1:4 ratio). 
 
 
Rf 0.29 (40 % Et2O : petroleum ether).  
1
H NMR (500 MHz, CDCl3) δ 6.91 (1H, dd, J 2.5 Hz, J 10.2 Hz, H-13), 6.13 (1H, d, J 
10.4 Hz, H-12) 5.71-5.63 (1H, m, H-14), 5.29 (1H, d, J 8.9 Hz, H-7), 4.91-4.85 (1H, m, 
H-10), 3.56-3.30 (2H, m, H-4), 2.69-2.53 (1H, m, H-5), 1.64 (3H, s, H-9), 1.0 (3H, d, J 
6.2 Hz, H-6), 0.88 (9 H, s, H-1), 0.03 (6H, s, H-3). 
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13
C NMR (125 MHz, CDCl3) δ 195.0 (C-11), 144.5 (C-13), 135.5 (C-7), 130.2 (C-8), 
128.1 (C-12), 87.9 (C-14), 80.7 (C-10), 67.5 (C-4), 35.3 (C-5), 25.9 (C-1), 18.4 (C-2), 
17.0 (C-6), 13.1 (C-9), -5.4 (C-3). 
HRMS (ESI) m/z =  349.1803 (calc. 349.1806) C17H30O4SiNa [M + Na]. 
νmax (thin film)/cm
-1
 3376 (br, O-H), 2957, 2930 and 2868 (m, C-H), 1691 (m, C=O), 
1469. 
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(2E,4Z,7S,8E,10S)-Ethyl 11-(t-butyldimethylsilyloxy)-7-hydroxy-2,8,10-trimethyl-6-
oxoundeca-2,4,8-trienoate (209) 
 
 
 
To a stirred solution of lactol (195) (500 mg, 1.53 mmol) in dry benzene was 
added phosphorane (203) (1.11g, 3.06 mmol) as a single portion at room temperature 
under a nitrogen atmosphere. The reaction mixture was stirred for 48 hours, before 
removing the solvent under reduced pressure. The crude material was purified by flash 
column chromatography using neutral silica (10 % Et2O : petroleum ether) and alcohol 
(209) was isolated as a yellow oil (533 mg, 85 %). 
 
Rf 0.27 (20 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 8.30 (1H, d, J 12.0 Hz, H-14), 6.90 (1H, dd app. t, J 11.8 
Hz, H-13), 6.34 (1H, d, J 11.7, H-12), 5.48 (1H, d, J 9.5 Hz, H-7), 4.56 (1H, s, H-10), 
4.26 (2H, q, J 6.8 Hz, H-18), 3.56-3.38 (2H, m, H-4), 2.67-2.52 (1H, m, H-5), 2.04 (3H, 
s, H-9/H-16), 1.47 (3H, s, H-9/H-16), 1.34 (3H, t, J 6.7 Hz, H-19), 0.99 (3H, d, J 4.9 Hz, 
H-6), 0.88 (9H, s, H-1), 0.04 (6H, s, H-3). 
13
C NMR (125 MHz, CDCl3) δ 199.9 (C-11), 167.7 (C-17), 138.4 (C-13), 137.7  
(C-15/C-8), 136.2 (C-7), 132.4 (C-15/C-8), 132.1 (C-14), 123.5 (C-12), 84.0 (C-10), 67.2 
(C-4), 61.2 (C-18), 35.6 (C-5), 25.9 (C-1), 18.4 (C-2), 17.0 (C-6), 14.2 (C-19), 12.8  
(C-16/C-9), 11.2 (C-16/C-9), -5.3 (C-3). 
HRMS (ESI) m/z = 433.2384 (calc. 433.2381) C22H38O5SiNa [M + Na]. 
νmax (thin film)/cm
-1
 3470 (br, O-H), 2962, 2927 and 2859 (m, C-H), 1714 (s, C=O), 
1620 (w, C=C), 1581, 1240, 1082, 1030. 
[α]D
32 
-110.8º (c 1.57 in CHCl3). 
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(2E,4Z,7S,8E,10S)-Ethyl 11-(t-butyldimethylsilyloxy)-2,8,10-trimethyl-6-oxo-7-
(triisopropylsilyloxy)undeca-2,4,8-trienoate (210) 
 
 
 
To a stirred solution of alcohol (209) (500 mg, 1.22 mmol) in CH2Cl2 (20 mL) 
was added 2,6-lutidine (0.43 mL, 3.66 mmol) at 0 °C under a nitrogen atmosphere, 
followed by triisopropylsilyl trifluoromethanesulfonate (0.66 mL, 2.44 mmol) drop wise. 
The reaction mixture was stirred at 0 °C for three hours, before adding to a solution of 
saturated aqueous sodium bicarbonate (100 mL). The layers were separated and the 
aqueous phase was extracted with CH2Cl2 (3 x 50 mL). The combined organic extracts 
were dried over magnesium sulfate, filtered and the solvent was removed under reduced 
pressure. The crude material was purified by flash column chromatography using neutral 
silica (2.5 % Et2O : petroleum ether) and silyl ether (210) was isolated as a bright yellow 
oil (587 mg, 85 %). 
 
 
Rf 0.41 (5 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 8.24 (1H, d, J 13.2 Hz, H-14), 6.91-6.77 (1H, m, H-13), 
6.63 (1H, d, J 12.8 Hz, H-12), 5.66 (1H, d, J 9.0 Hz, H-7), 4.42 (1H, s, H-10), 4.23 (2H, 
q, J 6.7 Hz, H-18), 3.52-3.30 (2H, m, H-4), 2.64-2.51 (1H, m, H-5), 2.00 (3H, s, H-
9/H16), 1.60 (3H, s, H-9/H-16), 1.32 (3H, t, J 7.1 Hz, H-19), 1.05-1.0 (21H, m, H-20 and 
H-21), 0.95 (3H, d, J 6.6 Hz, H-6), 0.87 (9H, s, H-1), 0.02 (6H, s, H-3). 
13
C NMR (125 MHz, CDCl3) δ  199.9 (C-11), 168.0 (C-17), 136.9 (C-13), 135.7  
(C-15/C-8), 132.8 (C-14), 132.2 (C-15/C-8), 131.1 (C-7), 125.0 (C-12), 83.7 (C-10), 67.6 
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(C-4), 61.0 (C-18), 35.2 (C-5), 25.9 (C-1), 18.3 (C-2), 17.9 (C-20), 17.0 (C-6), 14.2  
(C-19), 13.1 (C-16/C-9), 12.6 (C-16/C-9), 12.0 (C-21), -5.4 (C-3). 
HRMS (ESI) m/z =  589.3737 (calc. 589.3715) C31H58O5Si2Na [M + Na]. 
νmax (thin film)/cm
-1
 2932 and 2863 (m, C-H), 1710 (s, C=O), 1577, 1466, 1385, 1240, 
1090, 834. 
[α]D
28 
+43.9º (c 1.22 in CHCl3). 
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(2E,4Z,6S,7S,8E,10S)-Ethyl 11-(t-butyldimethylsilyloxy)-6-hydroxy-2,8,10- 
trimethyl-7-(triisopropylsilyloxy)undeca-2,4,8-trienoate (211) 
 
 
 
To a stirred solution of enone (210) (500 mg, 0.88 mmol) in methanol (20 mL) 
was added cerium trichloride heptahydrate (4.85 mL of a 0.2 M solution in methanol, 
0.97 mmol), at 0 °C under a nitrogen atmosphere, followed by sodium borohydride  
(37 mg, 0.97 mmol) as multiple portions. The effervescent mixture was stirred at  
0 °C for three hours, before removing the solvent under reduced pressure. The resultant 
material was taken up in CH2Cl2 (20 mL), washed with a solution of saturated aqueous 
sodium chloride (50 mL), and the aqueous layer was then extracted with CH2Cl2  
(3 x 20 mL). The combined organic extracts were dried over magnesium sulfate, filtered 
and the solvent was removed under reduced pressure. The crude material was purified by 
flash column chromatography using neutral silica (10 % Et2O : petroleum ether) and the 
resultant alcohol (211) was isolated as a pale yellow oil (470 mg, 94 %). 
 
Rf 0.19 (10 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 7.40 (1H, d, J 11.3 Hz, H-14), 6.39 (1H, dd app. t,  
J 12.1 Hz, H-13), 5.69-5.63 (1H, m, H-12), 5.14 (1H, d, J 5.5 Hz, H-7), 4.53 (1H, dd app. 
t, J 7.7 Hz, H-11), 4.26-4.11 (2H, m, H-18), 3.95 (1H, d, J 7.5 Hz, H-10), 3.51-3.40  
(1H, m, H-4), 3.34-3.24 (1H, m, H-4), 2.52-2.37 (1H, m, H-5), 1.91 (3H, s, H-9/H-16), 
1.65 (3H, s, H-9/H-16), 1.32-1.20 (3H, m, H-19), 1.07 (21H, br, s, H-20 and H-21), 0.88-
0.81 (12H, m, H-1 and H-6), 0.02 (6H, s, H-3). 
13
C NMR (125 MHz, CDCl3) δ 168.2 (C-17), 136.5 (C-12), 133.5 (C-8/C-15), 132.6  
(C-7), 132.5 (C-14), 128.8 (C-8/C-15), 126.5 (C-13), 82.2 (C-10), 69.7 (C-11), 67.2  
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(C-4), 60.6 (C-18), 35.2 (C-5), 25.9 (C-1), 18.4 (C-2), 18.1 (C-20), 16.6 (C-6), 14.3  
(C-19), 12.9 (C-21), 12.3 (C-9/C-16), 12.3 (C-9/C-16), -5.5 (C-3). 
HRMS (ESI) m/z = 591.3873 (calc. 591.3871) C31H60O5Si2Na [M + Na]. 
νmax (thin film)/cm
-1
 3530 (br, O-H), 2927 and 2859 (s, C-H), 1710 (s, C=O), 1462, 
1389,1248, 1082. 
[α]D
30 
-22.4º (c 1.32 in CHCl3). 
 145 
 
(2E,4Z,6S,7S,8E,10S)-Ethyl 11-(t-butyldimethylsilyloxy)-6-methoxy-2,8,10- 
trimethyl-7-(triisopropylsilyloxy)undeca-2,4,8-trienoate (213) 
 
 
 
To a stirred solution of alcohol (211) (400 mg, 0.70 mmol) in CH2Cl2 (50 mL) 
was added proton sponge
TM
 (1,8-bis(dimethylamino)naphthalene) (480 mg, 2.24 mmol) 
at room temperature under a nitrogen atmosphere,  followed by trimethyloxonium 
tetrafluoroborate (310 mg, 2.10 mmol) as multiple portions. The reaction mixture was 
stirred for five hours, before the addition of CH2Cl2 (150 mL) and of an aqueous solution 
of 1 M sodium dihydrogen phosphate (150 mL). The layers were separated and the 
aqueous phase was extracted with CH2Cl2 (3 x 100 mL). The combined organic extracts 
were washed with a solution of saturated aqueous sodium chloride (100 mL), dried over 
sodium sulfate, filtered and the solvent was removed under reduced pressure. The crude 
material was purified by flash column chromatography using neutral silica (5 % Et2O : 
petroleum ether) and ester (213) was isolated as a yellow oil (362 mg, 89 %). 
 
Rf 0.18 (25 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 7.50 (1H, d, J 12.0 Hz, H-14), 6.43 (1H, dd, J 11.4 Hz, 
11.6 Hz, H-13), 5.49-5.45 (1H, m, H-12), 5.14-5.06 (1H, m, H-7), 4.25-4.21 (2H, m,  
H-18), 4.12-4.09 (2H, m, H-10 and H-11), 3.46 (1H, dd, J 5.1 Hz, 9.7 Hz, H-4), 3.38-3.32 
(1H, m, H-4), 3.27 (3H, s, H-22), 2.51-2.42 (1H, m, H-5), 1.94 (3H, s, H-9/H-16), 1.58 
(3H, s, H-9/H-16), 1.31 (3H, t, J 7.1 Hz, H-19), 1.11-1.04 (24H, m, H-6, H-20 and H-21), 
0.88 (9H, s, H-1), 0.02 (6H, s, H-3). 
13
C NMR (125 MHz, CDCl3) δ 168.4 (C-17), 135.6 (C-12), 134.8 (C-8/C-15), 132.5  
(C-14), 130.9 (C-7), 128.9 (C-8/C-15), 126.8 (C-13), 80.8 (C-10/C-11), 80.6 (C-10/ 
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C-11), 67.5 (C-4), 60.6 (C-18), 56.8 (C-22), 35.1 (C-5), 25.9 (C-1), 18.3 (C-2), 18.0  
(C-20), 16.9 (C-6), 14.3 (C-19), 12.7 (C-21), 12.4 (C-16), 11.8 (C-9), -5.3 and -5.4 (C-3). 
HRMS (ESI) m/z = 605.4015 (calc. 605.4028) C32H62O5Si2Na [M + Na]. 
νmax (thin film)/cm
-1
 2940, 2863 (s, C-H), 1710 (s, C=O), 1466, 1389, 1363, 1252, 1094, 
881. 
[α]D
33 
-12.6º (c 2.38 in CHCl3). 
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(2E,4Z,6S,7S,8E,10S)-Ethyl 11-hydroxy-6-methoxy-2,8,10-trimethyl-7-
(triisopropylsilyloxy)undeca-2,4,8-trienoate (218) 
 
 
 
To a stirred solution of (213) (200 mg, 0.35 mmol) in tetrahydrofuran (5 mL) was 
added a pre-mixed solution of glacial acetic acid (5 mL) and water (2.5 mL) drop wise at 
room temperature under a nitrogen atmosphere. The reaction mixture was stirred 
overnight, before adding toluene (10 mL) and removing the solvent under reduced 
pressure. This process was repeated twice. The crude material was purified by flash 
column chromatography using neutral silica (20 % Et2O : petroleum ether) and alcohol 
(218) was isolated as a clear oil (164 mg, 100 %). 
 
Rf 0.18 (20 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 7.46 (1H, d, J 12.0 Hz, H-11), 6.44 (1H, dd app. t, J 11.4 
Hz, H-10), 5.53-5.38 (1H, m, H-9), 5.10 (1H, d, J 9.5 Hz, H-4), 4.20 (2H, q, J 7.0 Hz,  
H-15), 4.14-4.05 (2H, m, H-7 and H-8), 3.42-3.29 (2H, m, H-1), 3.24 (3H, s, H-19), 2.62-
2.48 (1H, m, H-2), 1.91 (3H, s, H-6/H-13), 1.66 (1H, br, s, H-20), 1.59 (3H, s, H-6/H-13), 
1.29 (3H, t, J 7.0 Hz, H-16), 1.04-1.00 (21 H, m, H-17 and H-18), 0.85 (3H, d, J 6.6 Hz, 
H-3). 
13
C NMR (125 MHz, CDCl3) δ 168.7 (C-14), 137.2 (C-5/C-12), 135.9 (C-9), 132.6  
(C-11), 130.7 (C-4), 129.6 (C-5/C-12), 127.4 (C-10), 80.9 (C-7/C-8), 80.8 (C-7/C-8), 
67.9 (C-1), 61.1 (C-15), 57.2 (C-19), 35.5 (C-2), 18.4 (C-17), 16.9 (C-3), 14.7 (C-16), 
13.7 (C-6/C-13), 12.8 (C-18), 12.7 (C-6/C/-13). 
HRMS (ESI) m/z = 491.3155 (calc. 491.3163) C26H48O5SiNa [M + Na]. 
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νmax (thin film)/cm
-1
 3468 (br, O-H), 2944 and 2867 (m, C-H), 1703 (m, C=O), 1635 (w, 
C=C), 1464, 1389, 1368, 1254, 1190, 1106, 1067, 1034, 997, 910, 883, 811, 735, 680, 
648. 
[α]D
33 
-20.4º (c 1.52 in CHCl3). 
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(2E,4Z,6S,7S,8E,10S)-Ethyl 6-methoxy-2,8,10-trimethyl-11-oxo-7- 
(triisopropylsilyloxy)undeca-2,4,8-trienoate (194) 
 
 
 
To a stirred solution of alcohol (218) (107 mg, 0.23 mmol) in CH2Cl2 (10 mL) 
was added 4 Å MS and N-methylmorpholine-N-oxide (32 mg, 0.27 mmol) at room 
temperature under a nitrogen atmosphere. The reaction mixture was stirred for 30 
minutes, before addition of tetrapropylammonium peruthenate (4 mg, 0.011 mmol) as a 
single portion. The reaction mixture was stirred for one hour, before removing the solvent 
under reduced pressure. The crude material was immediately purified by flash column 
chromatography (5 % Et2O : petroleum ether) and aldehyde (194) was isolated as a clear 
oil (75 mg, 70 %). 
 
Rf 0.5 (20 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 9.46 (1H, d, J 1.7 Hz, H-1), 7.46 (1H, d, J 12.0 Hz,  
H-11), 6.49-6.44 (1H, m, H-10), 5.46 (1H, dd app. t, J 10.3, H-9), 5.20 (1H, d, J 9.3, H-
4), 4.24-4.12 (4H, m, H-7, H-8 and H-15), 3.27 (3H, s, H-19), 3.25-3.18 (1H, m, H-2), 
1.93 (3H, s, H-6/H-13), 1.66 (3H, s, H-6/H-13), 1.30 (3H, t, J 7.1 Hz, H-16), 1.12-1.02 
(12 H, m, H-3, H-17 and H-18). 
13
C NMR (125 MHz, CDCl3) δ 200.8 (C-1), 168.2 (C-14), 140.1 (C-5/C-12), 135.0 (C-
9), 132.1 (C-11), 129.5 (C-5/C-12), 127.3 (C-10), 123.8 (C-4), 80.5 (C-7/C-8), 79.6  
(C-7/C8), 60.7 (C-15), 56.8 (C-19), 46.0 (C-2), 18.0 (C-17), 17.9 (C-3), 14.3 (C-16), 13.6 
(C-6/C-13), 12.4 (C-18), 12.3 (C-6/C-13). 
HRMS (ESI) m/z = 489.2999 (calc. 489.3007) C26H46O5SiNa [M + Na]. 
νmax (thin film)/cm
-1
 2936 and 2865 (s, C-H), 1711 (s, C=O), 1463, 1246, 1096. 
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[α]D
22 
+41.7º (c 0.67 in CHCl3). 
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11-Hydroxy-6-methoxy-2,8,10-trimethyl-7-triisopropylsilanyloxy-trideca-2,4,8,12-
tetraenoic acid ethyl ester (219) 
 
 
 
 
To a stirred solution of aldehyde (194) (310 mg, 1.63 mmol) in tetrahydrofuran  
(10 mL) under an atmosphere of nitrogen, was added vinyl magnesium bromide (1.63 
mL, 1.63 mmol) drop wise at 0˚C and the reaction mixture was stirred at room 
temperature overnight and was then quenched with a solution of saturated ammonium 
chloride (10 mL). The aqueous layer was then extracted with Et2O (3 x 10 mL). The 
organic extracts were combined and washed with brine (30 mL), dried over anhydrous 
magnesium sulfate, filtered and concentrated under reduced pressure. Flash 
chromatography (gradient of 0 to 15 % of Et2O in petroleum ether) afforded alcohol 
(219) as an orange oil (215 mg, 60 %). 
 
 
Rf 0.50 (20 % diethyl ether : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 6.53-6.45 (1H, m, H-12), 5.89-5.77 (1H, m, H-2), 5.48 
(1H, m, H-11), 5.23 (1H, m, H-6), 5.18-5.07 (2H, m, H-1), 4.27 (2H, m, H-17), 4.25-4.11 
(2H, m, H-9 and H-10), 3.91 (1H, m, H-3), 3.28 (3H, s, H-19), 2.37 (1H, m, H-4), 1.95 
(1H, m, H-8 or H-15), 1.66 (1H, m, H-8 or H-15), 1.32 (3H, t, J 10 Hz, H-18), 1.14-1.04 
(18H, d, J 10 Hz, H-19), 1.00 (1H, m, H-5), 0.97 (3H, q, J 10 Hz, H-20). 
13
C NMR (125 MHz, CDCl3) δ 168.0 (C-16), 139.1 (C-2), 137.8 (C-7 or C-14), 137.3 
(C-7 or C-14), 135.6 (C-11), 132.4 (C-13), 129.0 (C-6), 127.2 (C-12), 115.3 (C-1), 80.7 
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(C-9 or C-10), 76.5 (C-3), 60.7 (C-9 or C-10), 60.3 (C-17), 56.7 (C-19), 21.7 (C- 4), 18.1 
(C-21), 16.0 (C-20), 14.3 (C-18), 13.3 (C-8 or C-15), 12.6 (C-5), 12.5 (C-8 or C-15). 
HRMS (ESI) m/z = 517.3318 (calc. 517.3320) C28H50O5SiNa [M + Na]. 
νmax (thin film)/cm
-1
 2952, 1699, 1463, 1254, 1100, 907, 730. 
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2-[5-(tert-Butyl-dimethyl-silanyloxy)-2,4-dimethyl-1-triisopropylsilanyloxy-pent-2-
enyl]-furan (224) 
 
 
 
To a stirred solution of furyl acohol (196) (1.0 g, 3.2 mmol) in CH2Cl2 (50 mL) at 
0 °C under an atmosphere of nitrogen, was added 2,6-lutidine (1.2 mL, 9.7 mmol) and the 
reaction mixture was stirred at 0 °C for ten minutes. Then, tri-isopropylsilyl 
trifluoromethanesulfonate (1.8 mL, 6.4 mmol) was added drop wise at 0 °C. The reaction 
mixture was warmed to room temperature and stirred overnight and subsequently 
quenched with a solution of saturated aqueous sodium hydrocarbonate (40 mL). The 
layers were separated and the aqueous phase was extracted with CH2Cl2 (3 x 30 mL). The 
organic extracts were combined and dried over magnesium sulfate, filtered and the 
solvent was removed under reduced pressure. The crude material was purified by flash 
column chromatography (100 % petroleum ether) and the disilylated alcohol (224) was 
isolated as a colorless oil (70 mg, 40 %). 
 
Rf 0.73 (10 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 7.30 (1H, m, H-14), 6.28 (1H, m, H-12), 6.19 (1H, m, H-
13), 5.41 (1H, d, J 9.35 Hz, H-7), 3.34-3.54 (2H, m, H-4), 2.53-2.59 (1H, m, H-10), 1.58 
(3H, d, J 1.1Hz, H-6), 1.51 (3H, s, H-9), 1.25 (1H, m, H5), 1.01-1.12 (18H, m, H-16), 
0.96 (3H, m, H-15), 0.90 (9H, s, H-1), 0.04 (6H, s, H-3). 
13
C NMR (125 MHz, CDCl3) δ 156.8 (C-11), 141.1 (C-14), 135.6 (C-8), 129.3 (C-13), 
109.9 (C-12), 105.8 (C-7), 74.4 (C-10), 67.7 (C-4), 35.2 (C-5), 25.9 (C-1), 18.0 (C-2), 
17.9 (C-16), 17.1 (C-6), 12.3 (C-15), 12.1 (C-9), -5.4 (C-3). 
HRMS (ESI) m/z = 489.3178 (calc. 489.3191) C26H50O3Si2Na [M + Na].  
νmax (thin film)/cm
-1 
2927, 2865, 1463, 1252, 1083, 833.  
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[α]D
29 
+13.4º (c 0.54  in CHCl3). 
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(S,E)-1-(furan-2-yl)-5-hydroxy-2,4-dimethylpent-2-en-1-one (227) 
 
 
 
To a stirred solution of protected alcohol (205) (3.3 g, 10.7 mmol) in methanol  
(50 mL) at room temperature and under an atmosphere of nitrogen, was added pyridinium 
tribromide (320 mg, 0.53 mmol) and the reaction mixture was stirred at room temperature 
for 3 hours. The reaction mixture was then quenched with sodium bicarbonate (20 mL). 
The aqueous layer was then extracted (3 x 20 mL) with ethyl acetate. The combined 
organic extracts were dried with anhydrous magnesium sulfate, filtered and concentrated 
under reduced pressure. Flash chromatography (20 % Et2O : petroleum ether) afforded 
alcohol (227) as a yellowish oil (1.67 g, 80 %). 
 
Rf 0.37 (80 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 7.62 (1H, dd, JA 1.7 Hz, JB 0.7 Hz, H-11), 7.08 (1H, dd, 
JC 3.5 Hz, JB 0.7 Hz, H-9), 6.52-6.51 (1H, dd, JC 3.5 Hz, JA 1.7 Hz, H-10), 6.43-6.41 
(1H, d, J 11 Hz, H-4), 3.36-3.55 (2H, m, H-1), 2.90-2.87 (1H, m, H alkoxy), 2.00 (3H, s, 
H-6), 1.41 (1H, m, H-2), 1.10-1.09 (3H, d, J 8.8 Hz, H-3). 
13
C NMR (125 MHz, CDCl3) δ 185 (C-7), 153 (C-8), 157 (C-11), 145 (C-10), 137 (C-5), 
119 (C-9), 112 (C-4), 68 (C-1), 37 (C-2), 16 (C-3), 14 (C-6). 
HRMS (ESI) m/z = 217.0834 (calc. 217.0835) C11H14O3Na [M + Na]. 
νmax (thin film)/cm
-1 
3422, 2960, 2928, 1622, 1463. 
[α]D
25 
-8.6º (c 0.53 in CHCl3). 
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5-Furan-2-yl-2,4-dimethyl-5-oxo-pent-3-enal (231) 
 
 
 
To a stirred solution of alcohol (227) (2.2 g, 11.3 mmol) in CH2Cl2 (200 mL) at 
room temperature and under an atmosphere of nitrogen, was added Dess-Martin 
periodinane (7.2 g, 17.0 mmol) and the reaction mixture was stirred at room temperature 
overnight. The reaction mixture was then quenched with sodium thiosulfate (100 mL) 
and sodium bicarbonate (100 mL). The aqueous layer was then extracted with CH2Cl2 (3 
x 100 mL). The organic extracts were combined and washed with brine (100 mL), dried 
over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. 
Flash chromatography (10 % Et2O : petroleum ether) afforded aldehyde (231) as a 
yellowish oil (1.44 g, 67 %). 
 
Rf 0.57 (80 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 9.45 (1H, s, H-1), 7.61 (1H, dd, JA 1.7 Hz, JB 0.7 Hz,  
H-11), 7.27 (1H, d, JB 0.7 Hz, H-9), 6.65 (1H, d, J 9.7 Hz, H-4), 6.58-6.57 (1H, dd,  
J 3.7 Hz, JA 1.7Hz, H-10), 4.46-4.43 (1H, m, H-2), 1.88 (3H, s, H-6), 1.42-1.40 (3H, d,  
J 7 Hz, H-3). 
13
C NMR (125 MHz, CDCl3) δ 194 (C-1), 188 (C-7), 152 (C-8), 151 (C-11), 139 (C-10), 
139 (C-5), 118 (C-9), 113 (C-4), 42 (C-2), 17 (C-3), 9.5 (C-6). 
HRMS (ESI) m/z = 215.0679 (calc. 215.0679) C11H12O3Na [M + Na]. 
νmax (thin film)/cm
-1 
1671, 1463. 
[α]D
25 
+3.6º (c 0.55 in CHCl3). 
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1-Furan-2-yl-5-hydroxy-2,4-dimethyl-hepta-2,6-dien-1-one (232) 
 
 
 
To a stirred solution of aldehyde (231) (1.25 g, 6.51 mmol) in tetrahydrofuran  
(50 mL) under an atmosphere of nitrogen, was added vinyl magnesium bromide (6.51 
mL, 6.51 mmol) drop wise at 0˚C and the reaction mixture was stirred at room 
temperature overnight. The reaction mixture was then quenched with a solution of 
saturated ammonium chloride (40 mL). The aqueous layer was then extracted with Et2O 
(3 x 50 mL). The organic extracts were combined and washed with brine (100 mL), dried 
over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. 
Flash chromatography (gradient of 0 to 15 % of Et2O in petroleum ether) afforded 
alcohol (232) as an orange oil (0.86 g, 60 %). 
 
Rf 0.40 (50 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 7.58 (1H, d, J 1Hz, H-13), 7.20-7.18 (1H, m, H-11), 6.53 
(1H, m, H-12), 5.86-5.77 (1H, m, H-2), 5.62-5.61 (1H, d, J 9.5 Hz, H-6), 5.30-5.17 (2H, 
m, H-1), 4.54 (1H, d, J 4.8 Hz, H-3), 4.16-4.12 (1H, m, H-4), 1.73 (3H, s, H-8), 1.62 (1H, 
s, alkoxy), 1.30-1.26 (3H, m, H-5). 
13
C NMR (125 MHz, CDCl3) δ 191 (C-9), 152 (C-10), 146 (C-13), 139 (C-2), 138 (C-7), 
126 (C-11), 117 (C-6), 115 (C-1), 112 (C-12), 78 (C-3), 41 (C-4), 17 (C-5), 12 (C-8). 
HRMS (ESI) m/z = 243.0994 (calc. 243.0992) C13H16O3Na [M + Na]. 
νmax (thin film)/cm
-1 
3441 (alcohol), 2927, 1659, 1464. 
[α]D
26 
+22.9º (c 1.01 in CHCl3). 
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Propionic acid 5-furan-2-yl-2,4-dimethyl-5-oxo-1-vinyl-pent-3-enyl ester (233) 
 
 
 
To a stirred solution of alcohol (232) (160 mg, 0.73  mmol) in CH2Cl2 (10 mL) 
under an atmosphere of nitrogen was added 2-6 lutidine (0.08 mL, 0.87 mmol) at 0˚C. 
The reaction mixture was stirred at 0˚C for 10 minutes and propionyl chloride (0.08 mL, 
0.87 mmol) was added drop wise at 0˚C. The reaction mixture was then allowed to warm 
up to room temperature, stirred overnight and was then quenched with a 2M aqueous 
solution of hydrochloric acid (5 mL). The aqueous layer was then extracted with CH2Cl2 
(3 x 50 mL). The organic extracts were combined, dried over anhydrous magnesium 
sulfate, filtered and concentrated under reduced pressure. Flash chromatography (10 % 
Et2O : petroleum ether) afforded ester (233) as a yellowish / orange oil (180 mg, 89 %). 
 
Rf 0.63 (50 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 7.57 (1H, d, J 0.6 Hz, H-13), 7.19-7.17 (1H, m, H-11), 
6.53-6.52 (1H, m, H- 12), 5.75-5.73 (1H, m, H-2), 5.63 (1H, d, J 9 Hz, H-6), 5.59 (1H, m, 
H-4), 5.25-5.15 (2H, m, H-1), 4.15-4.08 (1H, m, H-3), 2.37-2.32 (2H, m, H-15), 1.74 
(1H, s, H-8), 1.28-1.26 (3H, m, H-5), 1.15-1.12 (3H, m, H-16). 
13
C NMR (125 MHz, CDCl3) δ 190.3 (C-9), 173.1 (C-14), 152.1 (C-10), 146.3 (C-13), 
135.1 (C-2/6), 134.5 (C-7), 127.4 (C-2/6), 117.4 (C-11/12), 116.9 (C-1), 112.2 (C-11/12), 
78.8 (C-3), 41.3 (C-4), 27.9 (C-15), 17.2 (C-5/8), 13.2 (C-5/8), 9.1 (C-16). 
HRMS (ESI) m/z = 299.1259 (calc. 299.1254) C16H20O4Na [M + Na]. 
νmax (thin film)/cm
-1 
2980, 1735, 1677, 1465.  
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(4S,7S,E)-7-(furan-2-yl)-7-hydroxy-4,6-dimethylhepta-1,5-dien-3-yl 
propionate (234) 
 
 
 
To a stirred solution of lithium aluminium hydride (275 mg, 7.24 mmol) in Et2O 
(10 mL) at 0 °C under an atmosphere of nitrogen, was added a solution of (1R),(2S)-(-)-
N-methylephedrine (1.3 g, 7.24 mmol) in Et2O (30 mL) drop wise. The reaction mixture 
was submitted to reflux for two hours, before being allowed to cool to room temperature. 
A solution of freshly distilled N-ethylaniline (1.82 mL, 14.5 mmol) in Et2O (10 mL) was 
added drop wise and the reaction mixture was submitted to reflux for a further two hours. 
The reaction mixture was cooled down to -100 °C and a solution of furyl ketone (233) 
(1.2 g, 4.34 mmol) in Et2O (30 mL) was added drop wise. The reaction mixture was 
stirred at -100 °C for four hours, before subsequently being quenched by pouring into an 
ice cooled aqueous solution of sodium potassium tartrate (10 g) and water (50 mL). The 
solution was allowed to warm to room temperature overnight. The layers were separated 
and the aqueous phase was extracted with Et2O (3 x 50 mL). The combined organic 
extracts were washed with a solution of saturated aqueous copper sulfate (50 mL), a 
solution of saturated aqueous sodium chloride (2 x 50 mL) dried over magnesium sulfate, 
filtered and the solvent was removed under reduced pressure. The crude material was 
purified by flash column chromatography (5 % Et2O : petroleum ether) and furyl alcohol 
(234) was isolated as a clear oil (860 mg, 71 %). 
 
Rf 0.35 (30 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 7.38 (1H, s, H-13), 6.33 (1H, dd, J 2.6, 10 Hz, H-12), 
6.25 (1H, dd, J 2.6, 10 Hz, H-11), 5.82 (1H, m, H-2), 5.59 (1H, t, J 6.0 Hz, H-3), 5.43 
(1H, d, J 10 Hz, H-6), 5.30-5.26 (2H, m, H-1), 4.42 (1H, d, J 7.85 Hz, H-4), 2.95 (1H, m, 
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H-9), 2.36 (2H, m, H-15), 1.67 (3H, d, J 13 Hz, H-5), 1.08 (3H, m, H-16), 0.89 (3H, d, 
6.75 Hz). 
13
C NMR (125 MHz, CDCl3) δ 173 (C-14), 155 (C-10), 142 (C-13), 135 (C-2), 130  
(C-7), 129 (C-6), 116 (C-1), 110 (C-12), 107 (C-11), 79 (C-3), 72 (C-4), 38 (C-9), 28 (C-
15), 17 (C-8), 13 (C-5), 9 (C-19). 
HRMS (ESI) m/z = 301.1414 (calc.301.1410) C16H22O4SiNa [M + Na]. 
νmax (thin film)/cm
-1 
3459, 2979, 2930, 2876, 1729, 1358, 1182. 
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(4E,6R,7E,9S)-tert-butyldimethylsilyl-9-(furan-2-yl)-9-hydroxy-2,6,8-trimethyl 
nona-4,7-dienoate (247) 
 
 
 
To a stirred solution of diisopropylamine (0.76 mL, 5.5 mmol) in tetrahydrofuran (25 
mL) was added n-butyllithium (2.2 mL, 2.5M in hexanes, 5.5 mmol) at 0 °C. The 
solution was stirred at 0 °C for 15 min and cooled to -78 °C. Hexamethylphosphoramide 
(1.9 mL, 11.0 mmol) and tetrahydrofuran (1.9 mL) were then successively added. The 
solution became light yellow and after 10 min, a solution of propionate (234) (300 mg, 
1.1 mmol) in tetrahydrofuran (2 µL) was slowly added. The resulting solution was 
stirred at -78 °C for 45 min by which time the color became bright yellow. A solution of 
tert-butyldimethylsilyl chloride (1.32 mg, 8.8 mmol) in tetrahydrofuran (30 mL) was 
then added. The solution became light yellow and after 15 min at -78 °C the reaction 
mixture was gradually warmed to rt over 2h. The solution was then stirred at rt. for 7 h 
and quenched with 1M aqueous hydrochloric acid (50 mL). The aqueous phase was 
extracted with ethyl acetate (3 x 50 mL). The organic extracts were combined, dried 
over sodium sulfate, filtered and concentrated under reduced pressure. The residue was 
purified by flash chromatography (gradient from 10 % ethyl acetate : petroleum to 30 % 
ethyl acetate : petroleum) to afford the corresponding silyl ester (247) (traces) as a 
colourless oil. 
 
Rf 0.75 (5 % Et2O : petroleum ether). 
1
H NMR (500 MHz, CDCl3) δ 7.33 (1H, d, J 14 Hz, H-16), 6.27 (1H, t, J 11 Hz, H-15), 
6.10 (1H, m, H-14), 6.01 (1H, t, J 14 Hz, H-6) 5.47 (1H, m, H-5), 5.23 (1H, d, J 10 Hz, 
H-9), 4.45 (1H, m, H-12), 2.94 (1H, m, H-7), 2.54 (1H, m, H-2), 2.23 (2H, m, H-4), 
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1.70 (3H, d, J 11 Hz, H-8), 1.19 (3H, m, H-3), 1.02 (3H, m, H-11), 0.87 (9H, d, J 14 Hz, 
H-19), 0.11 (6H, s, H-17). 
13
C NMR (125 MHz, CDCl3) δ 181 (C-1), 156 (C-13), 141 (C-16), 137 (C-6), 134 (C-
9), 123 (C-5), 110 (C-15), 105 (C-14), 73 (C-12), 40 (C-2), 39 (C-7), 38 (C-10), 36 (C-
4), 26 (C-19), 18 (C-18), 17 (C-3), 16 (C-11), 14 (C-8), -5 (C-17). 
HRMS (ESI) m/z = 415.2265 (calc. 415.2275) C22H36O4SiNa [M + Na]. 
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4-methoxy-2-nitrophenol (260) 
 
 
 
To a stirred solution of 4-methoxy-2-phenol (252) (0.67 g, 0.54 mmol) in ethanol 
(50 mL) was added glacial acetic acid (2 mL) at room temperature, followed by a solution 
of sodium nitrite (0.6 g, 0.9 mmol) in ethanol (30 mL) drop wise over 30 minutes. The 
resulting mixture was stirred overnight and subsequently quenched with 20% aqueous 
potassium hydroxide solution (50 mL). Et2O (100 mL) was then added to the solution 
which was stirred 30 minutes. The layers were then separated and the aqueous phase 
was extracted with Et2O (3 x 50 mL). The combined organic extracts were dried over 
magnesium sulfate, filtered and the solvent was removed under reduced pressure. The 
crude material was purified by flash column chromatography (100 % toluene) and 4-
methoxy-2-nitrophenol (260) was isolated as an orange solid (0.5 g, 54 %). 
 
Rf 0.82  (Toluene). 
1
H NMR (500 MHz, CDCl3) δ 10.40 (1H, s, OH), 7.52 (1H, d, J 2.0 Hz, H-3), 7.24  
(1H, dd, J 2.0, 8.4 Hz, H-5), 7.10 (1H, d, J 8.4 Hz, H-6), 3.84 (3H, s, H-7). 
13
C NMR (125 MHz, CDCl3) δ 153.0 (C-4), 150.5 (C-1), 134.0 (C-2), 127.7 (C-5), 
121.3 (C-6), 106.1 (C-3), 56.4 (C-7). 
LRMS (EI) m/z = 169 (calc.169.137) C7H7NO4. 
νmax (thin film)/cm
-1
 3227, 1523, 1244, 1216, 1027. 
mp 82°C (lit.
136
 83°C). 
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1-bromo-2,5-dimethoxy-3-nitrobenzene (251) 
 
 
 
To a stirred solution of 4-methoxy-2-nitrophenol (260) (8.31 g, 49.2 mmol) in 
glacial acetic acid (50 mL) was added a solution of bromine (2.5 mL, 49.2 mmol) in glacial 
acetic acid (10 mL) over 40 min. After stirring for 30 minutes at room temperature and 
heating at reflux for 5 hours, the reaction mixture was poured into water (750 mL) and 
acidified with conc. hydrochloric acid (10 mL). After filtration and drying, the desired 2-
bromo-4-methoxy-6-nitrophenol was obtained as an orange solid (9.3 g, 76%). 2-bromo-4-
methoxy-6-nitrophenol (9.3 g, 37.4 mmol) was then taken up in dry acetone (300 mL), 
and potassium carbonate (15.5 g, 112 mmol) and dimethyl sulfate (7.1 mL, 74.8 mmol) 
were added. The reaction mixture was heated at reflux for 5 hours and was then 
concentrated under reduced pressure. The residue was purified by flash chromatography 
(100 % toluene) and the desired aryl bromide (251) was obtained as a yellow solid (8.8 
g, 90 %). 
 
Rf 0.75 (Toluene). 
1
H NMR (500 MHz, CDCl3) δ 7.34 (1H, d, J 3.1 Hz, H-4), 7.28 (1H, d, J 3.1Hz,  
H-6), 3.96 (s, 3H, H-7), 3.83 (s, 3H, H-8). 
13
C NMR (125 MHz, CDCl3) δ 155.5 (C-5), 145.0 (C-2), 144.5 (C-3), 123.8 (C-6), 
120.1 (C-1), 109.2 (C-4), 62.7 (C-7), 56.3 (C-8). 
LRMS (EI) m/z = 261 and 263 (1:1 ratio). 
νmax (thin film)/cm
-1
 1524, 1341, 1229, 1077, 1043, 984, 860, 777. 
mp 98°C (lit.
137
 98-98.5 °C). 
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3-bromo-2,5-dimethoxyaniline (261) 
 
 
 
To a stirred suspension of nitro compound (251) (1.0 g, 3.8 mmol) in water (13 
mL) were added glacial acetic acid (0.15 mL) and iron (powder, 1.5 g). After 1.5 h of 
heating at reflux, the reaction mixture was filtered. The aqueous layer was basified with 
a saturated aqueous solution of sodium carbonate and extracted with ethyl acetate  
(2x 50 mL). The combined organic layers were dried over magnesium sulfate, filtered 
and concentrated under reduced pressure to provide the crude aniline (261) as a brown 
viscous oil (758 mg, 86%). 
 
1
H NMR (500 MHz, CDCl3) δ6.45 (1H, d, J = 3.0 Hz, H-4); 6.23 (1H, d, J = 2.5 Hz,  
H-6); 3.93 (2H, b, NH2); 3.78 (3H, s, H-6); 3.71 (3H, s, H-4). 
13
C NMR (125 MHz, CDCl3) δ δ 156.9 (C-5), 141.7 (C-2), 138.7 (C-1), 117.1 (C-3), 
107.1 (C-4), 101.3 (C-6), 59.9 (C-8), 55.7 (C-7). 
HRMS (ESI) m/z = 231, 233 (1:1 ratio). 
νmax (thin film)/cm
-1
 3468, 3370, 2936, 2830, 1612, 1565, 1486, 1431, 1222, 1152, 
1037, 990, 832. 
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